Raras
Buscar doenças, sintomas, genes...
Distrofia muscular
ORPHA:98473CID-10 · G71.0CID-11 · 8C70PCDT · SUSDOENÇA RARA

A distrofia muscular (DM) refere-se a um grupo de mais de 30 doenças genéticas caracterizadas por fraqueza progressiva e degeneração dos músculos esqueléticos que controlam o movimento. Algumas formas de DM são observadas em recém-nascidos, bebés ou crianças, enquanto outras têm início tardio e podem não aparecer até à meia-idade ou mais tarde. Os distúrbios diferem em termos de distribuição e extensão da fraqueza muscular (algumas formas de DM também afetam o músculo cardíaco), idade de início, taxa de progressão e padrão de herança. O prognóstico para pessoas com DM varia de acordo com o tipo e progressão do transtorno. Não existe tratamento específico para interromper ou reverter qualquer forma de DM. O tratamento é de suporte e pode incluir fisioterapia, terapia respiratória, fonoaudiologia, aparelhos ortopédicos usados ​​para suporte, cirurgia ortopédica corretiva e medicamentos, incluindo corticosteróides, anticonvulsivantes (medicamentos para convulsões), imunossupressores e antibióticos. Alguns indivíduos podem precisar de ventilação assistida para tratar fraqueza muscular respiratória ou de marcapasso para anormalidades cardíacas.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A distrofia muscular (DM) refere-se a um grupo de mais de 30 doenças genéticas caracterizadas por fraqueza progressiva e degeneração dos músculos esqueléticos que controlam o movimento. Algumas formas de DM são observadas em recém-nascidos, bebés ou crianças, enquanto outras têm início tardio e podem não aparecer até à meia-idade ou mais tarde. Os distúrbios diferem em termos de distribuição e extensão da fraqueza muscular (algumas formas de DM também afetam o músculo cardíaco), idade de início, taxa de progressão e padrão de herança. O prognóstico para pessoas com DM varia de acordo com o tipo e progressão do transtorno. Não existe tratamento específico para interromper ou reverter qualquer forma de DM. O tratamento é de suporte e pode incluir fisioterapia, terapia respiratória, fonoaudiologia, aparelhos ortopédicos usados ​​para suporte, cirurgia ortopédica corretiva e medicamentos, incluindo corticosteróides, anticonvulsivantes (medicamentos para convulsões), imunossupressores e antibióticos. Alguns indivíduos podem precisar de ventilação assistida para tratar fraqueza muscular respiratória ou de marcapasso para anormalidades cardíacas.

Pesquisas ativas
29 ensaios
856 total registrados no ClinicalTrials.gov
Publicações científicas
29.210 artigos
Último publicado: 2026 Apr 13
Medicamentos
2 registrados
ETEPLIRSEN, ATALUREN

Tem tratamento?

2 medicamentos registrados
Ver detalhes, fases e interações →
ETEPLIRSENATALUREN
🏥
SUS: Cobertura parcialScore: 50%
PCDT disponívelCID-10: G71.0
🇧🇷Dados SUS / DATASUS2024
2.340
internações/ano
R$ 6.780
custo médio/internação
ESTADOS COM MAIS INTERNAÇÕES
SPRJMGRSPR
PROCEDIMENTOS SIGTAP (2)
0202010694
Sequenciamento completo do exoma (WES)genetic_test
0301070040
Atendimento em reabilitação — doenças rarasrehabilitation
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

💪
Músculos
182 sintomas
🧠
Neurológico
88 sintomas
🦴
Ossos e articulações
68 sintomas
👁️
Olhos
54 sintomas
❤️
Coração
48 sintomas
😀
Face
36 sintomas

+ 363 sintomas em outras categorias

Características mais comuns

Orelhas de implantação baixa
Amplitude diminuída do potencial de ação muscular composto
Dificuldades alimentares
Hiperceratose folicular
Sinequias posteriores da câmara anterior
Aumento do tecido conjuntivo
962sintomas
Sem dados (962)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 962 características clínicas mais associadas, ordenadas por frequência.

Orelhas de implantação baixaLow-set ears
Amplitude diminuída do potencial de ação muscular compostoDecreased compound muscle action potential amplitude
Dificuldades alimentaresFeeding difficulties
Hiperceratose folicularFollicular hyperkeratosis
Sinequias posteriores da câmara anteriorPosterior synechiae of the anterior chamber

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico29.210PubMed
Últimos 10 anos200publicações
Pico2026196 papers
Linha do tempo
2026Hoje · 2026🧪 1978Primeiro ensaio clínico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

62 genes identificados com associação a esta condição.

DMDDystrophinCandidate gene tested inAltamente restrito
FUNÇÃO

Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. Component of the dystrophin-associated glycoprotein complex which accumulates at the neuromuscular junction (NMJ) and at a variety of synapses in the peripheral and central nervous systems and has a structural function in stabilizing the sarcolemma. Also implicated in signaling events and synaptic transmission

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeletonPostsynaptic cell membrane

VIAS BIOLÓGICAS (3)
Formation of the dystrophin-glycoprotein complex (DGC)Non-integrin membrane-ECM interactionsStriated Muscle Contraction
MECANISMO DE DOENÇA

Duchenne muscular dystrophy

Most common form of muscular dystrophy; a sex-linked recessive disorder. It typically presents in boys aged 3 to 7 year as proximal muscle weakness causing waddling gait, toe-walking, lordosis, frequent falls, and difficulty in standing up and climbing up stairs. The pelvic girdle is affected first, then the shoulder girdle. Progression is steady and most patients are confined to a wheelchair by age of 10 or 12. Flexion contractures and scoliosis ultimately occur. About 50% of patients have a lower IQ than their genetic expectations would suggest. There is no treatment.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
44.5 TPM
Artéria tibial
28.2 TPM
Aorta
27.2 TPM
Cólon sigmoide
25.6 TPM
Músculo esquelético
23.1 TPM
OUTRAS DOENÇAS (6)
Duchenne muscular dystrophyBecker muscular dystrophydilated cardiomyopathy 3Bsymptomatic form of muscular dystrophy of Duchenne and Becker in female carriers
HGNC:2928UniProt:P11532
COL12A1Collagen alpha-1(XII) chainCandidate gene tested inAltamente restrito
FUNÇÃO

Type XII collagen interacts with type I collagen-containing fibrils, the COL1 domain could be associated with the surface of the fibrils, and the COL2 and NC3 domains may be localized in the perifibrillar matrix

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (3)
Collagen degradationAssembly of collagen fibrils and other multimeric structuresCollagen biosynthesis and modifying enzymes
MECANISMO DE DOENÇA

Ullrich congenital muscular dystrophy 2

A form of Ullrich congenital muscular dystrophy, a disease characterized by generalized muscle weakness and striking hypermobility of distal joints in conjunction with variable contractures of more proximal joints and normal intelligence. Additional findings may include kyphoscoliosis, protruded calcanei, and follicular hyperkeratosis (rough skin). More severely affected patients manifest at birth and never achieve independent ambulation, while patients with milder phenotypes might maintain ambulation into adulthood. UCMD2 is a severe, autosomal recessive form with onset at birth.

OUTRAS DOENÇAS (4)
Ullrich congenital muscular dystrophy 2Bethlem myopathy 2Bethlem myopathyUllrich congenital muscular dystrophy
HGNC:2188UniProt:Q99715
DPM3Dolichol-phosphate mannosyltransferase subunit 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Stabilizer subunit of the dolichol-phosphate mannose (DPM) synthase complex; tethers catalytic subunit DPM1 to the endoplasmic reticulum

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (4)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM1 causes DPM1-CDGDefective DPM2 causes DPM2-CDG
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B15

An autosomal recessive, congenital muscular disorder characterized by hyperCKemia, myopathic features observed on muscle biopsy, developmental delay, mildly impaired intellectual development with learning difficulties, epilepsy, and mild white matter abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
101.0 TPM
Tireoide
86.4 TPM
Útero
85.8 TPM
Cervix Endocervix
81.3 TPM
Fallopian Tube
79.3 TPM
OUTRAS DOENÇAS (2)
DPM3-congenital disorder of glycosylationmuscular dystrophy-dystroglycanopathy (congenital with impaired intellectual development), type B, 15
HGNC:3007UniProt:Q9P2X0
POMGNT1Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Participates in O-mannosyl glycosylation by catalyzing the addition of N-acetylglucosamine to O-linked mannose on glycoproteins (PubMed:11709191, PubMed:27493216, PubMed:28512129). Catalyzes the synthesis of the GlcNAc(beta1-2)Man(alpha1-)O-Ser/Thr moiety on alpha-dystroglycan and other O-mannosylated proteins, providing the necessary basis for the addition of further carbohydrate moieties (PubMed:11709191, PubMed:27493216). Is specific for alpha linked terminal mannose and does not have MGAT3,

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (3)
DAG1 core M1 glycosylationsDAG1 core M2 glycosylationsMatriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3

An autosomal recessive disorder characterized by congenital muscular dystrophy, ocular abnormalities, cobblestone lissencephaly, and cerebellar and pontine hypoplasia. Patients present severe congenital myopia, congenital glaucoma, pallor of the optic disks, retinal hypoplasia, intellectual disability, hydrocephalus, abnormal electroencephalograms, generalized muscle weakness and myoclonic jerks. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
61.9 TPM
Tireoide
61.2 TPM
Brain Spinal cord cervical c-1
57.1 TPM
Testículo
54.0 TPM
Nervo tibial
52.7 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3retinitis pigmentosa 76autosomal recessive limb-girdle muscular dystrophy type 2O
HGNC:19139UniProt:Q8WZA1
PLECPlectinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Interlinks intermediate filaments with microtubules and microfilaments and anchors intermediate filaments to desmosomes or hemidesmosomes. Could also bind muscle proteins such as actin to membrane complexes in muscle. May be involved not only in the filaments network, but also in the regulation of their dynamics. Structural component of muscle. Isoform 9 plays a major role in the maintenance of myofiber integrity

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell junction, hemidesmosomeCell projection, podosome

VIAS BIOLÓGICAS (3)
Caspase-mediated cleavage of cytoskeletal proteinsType I hemidesmosome assemblyAssembly of collagen fibrils and other multimeric structures
MECANISMO DE DOENÇA

Epidermolysis bullosa simplex 5C, with pyloric atresia

A form of epidermolysis bullosa, a genodermatosis characterized by recurrent blistering, fragility of the skin and mucosal epithelia, and erosions caused by minor mechanical trauma. EBS5C is an autosomal recessive disorder characterized by severe skin blistering at birth and congenital pyloric atresia. Death usually occurs in infancy.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
241.5 TPM
Fibroblastos
212.0 TPM
Músculo esquelético
151.2 TPM
Aorta
144.6 TPM
Artéria tibial
138.0 TPM
OUTRAS DOENÇAS (6)
autosomal recessive limb-girdle muscular dystrophy type 2Qepidermolysis bullosa simplex 5A, Ogna typeepidermolysis bullosa simplex 5C, with pyloric atresiaepidermolysis bullosa simplex 5B, with muscular dystrophy
HGNC:9069UniProt:Q15149
ABCD3ATP-binding cassette sub-family D member 3Candidate gene tested inRestrito
FUNÇÃO

Broad substrate specificity ATP-dependent transporter of the ATP-binding cassette (ABC) family that catalyzes the transport of long-chain fatty acids (LCFA)-CoA, dicarboxylic acids-CoA, long-branched-chain fatty acids-CoA and bile acids from the cytosol to the peroxisome lumen for beta-oxydation (PubMed:11248239, PubMed:24333844, PubMed:25168382, PubMed:29397936). Has fatty acyl-CoA thioesterase and ATPase activities (PubMed:29397936). Probably hydrolyzes fatty acyl-CoAs into free fatty acids pr

LOCALIZAÇÃO

Peroxisome membrane

VIAS BIOLÓGICAS (2)
ABC transporters in lipid homeostasisClass I peroxisomal membrane protein import
MECANISMO DE DOENÇA

Congenital bile acid synthesis defect 5

An autosomal recessive disorder characterized by hepatosplenomegaly, hepatic fibrosis, progressive liver failure, and accumulation of peroxisomal C27-bile acid intermediates in plasma.

OUTRAS DOENÇAS (2)
congenital bile acid synthesis defect 5oculopharyngodistal myopathy
HGNC:67UniProt:P28288
CHKBCholine/ethanolamine kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Has a key role in phospholipid metabolism, and catalyzes the first step of phosphatidylethanolamine and phosphatidylcholine biosynthesis

LOCALIZAÇÃO

VIAS BIOLÓGICAS (2)
Synthesis of PCSynthesis of PE
MECANISMO DE DOENÇA

Muscular dystrophy, congenital, megaconial type

An autosomal recessive, congenital muscular dystrophy characterized by early-onset muscle wasting, intellectual disability, and dilated cardiomyopathy in half of affected individuals. Some patients may die from cardiomyopathy in the first or second decade of life. Muscle biopsy shows peculiar enlarged mitochondria that are prevalent toward the periphery of the fibers but are sparse in the center.

OUTRAS DOENÇAS (2)
megaconial type congenital muscular dystrophyproximal myopathy with focal depletion of mitochondria
HGNC:1938UniProt:Q9Y259
LARGE1Xylosyl- and glucuronyltransferase LARGE1Candidate gene tested inTolerante
FUNÇÃO

Bifunctional glycosyltransferase with both alpha-1,3-xylosyltransferase and beta-1,3-glucuronyltransferase activities involved in the maturation of alpha-dystroglycan (DAG1) by glycosylation leading to DAG1 binding to laminin G-like domain-containing extracellular proteins with high affinity (PubMed:15661757, PubMed:15752776, PubMed:21987822, PubMed:22223806, PubMed:23125099, PubMed:25279697, PubMed:25279699). Elongates the glucuronyl-beta-1,4-xylose-beta disaccharide primer structure initiated

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B6

A congenital muscular dystrophy associated with profound intellectual disability, white matter changes and structural brain abnormalities. Skeletal muscle biopsies show reduced immunolabeling of alpha-dystroglycan.

EXPRESSÃO TECIDUAL(Ubíquo)
Cólon sigmoide
22.7 TPM
Útero
20.5 TPM
Coração - Ventrículo esquerdo
17.8 TPM
Fallopian Tube
16.4 TPM
Cervix Ectocervix
15.9 TPM
OUTRAS DOENÇAS (5)
muscular dystrophy-dystroglycanopathy type B6muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A6muscle-eye-brain diseasemuscular dystrophy-dystroglycanopathy, type A
HGNC:6511UniProt:O95461
LTBP4Latent-transforming growth factor beta-binding protein 4Candidate gene tested inTolerante
FUNÇÃO

Key regulator of transforming growth factor beta (TGFB1, TGFB2 and TGFB3) that controls TGF-beta activation by maintaining it in a latent state during storage in extracellular space. Associates specifically via disulfide bonds with the Latency-associated peptide (LAP), which is the regulatory chain of TGF-beta, and regulates integrin-dependent activation of TGF-beta

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (2)
Molecules associated with elastic fibresTGF-beta receptor signaling activates SMADs
MECANISMO DE DOENÇA

Urban-Rifkin-Davis syndrome

A syndrome characterized by disrupted pulmonary, gastrointestinal, urinary, musculoskeletal, craniofacial and dermal development. Clinical features include cutis laxa, mild cardiovascular lesions, respiratory distress with cystic and atelectatic changes in the lungs, and diverticulosis, tortuosity and stenosis at various levels of the intestinal tract. Craniofacial features include microretrognathia, flat midface, receding forehead and wide fontanelles.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
752.6 TPM
Nervo tibial
709.9 TPM
Artéria coronária
541.5 TPM
Útero
513.5 TPM
Vagina
459.0 TPM
INTERAÇÕES PROTEICAS (4)
OUTRAS DOENÇAS (2)
cutis laxa with severe pulmonary, gastrointestinal and urinary anomaliesDuchenne muscular dystrophy
HGNC:6717UniProt:Q8N2S1
NOTCH2NLCNotch homolog 2 N-terminal-like protein CDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Human-specific protein that promotes neural progenitor proliferation and evolutionary expansion of the brain neocortex by regulating the Notch signaling pathway (PubMed:29561261, PubMed:29856954, PubMed:29856955). Able to promote neural progenitor self-renewal, possibly by down-regulating neuronal differentiation genes, thereby delaying the differentiation of neuronal progenitors and leading to an overall final increase in neuronal production (PubMed:29856954). Acts by enhancing the Notch signal

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (2)
Expression of NOTCH2NL genesNOTCH2 Activation and Transmission of Signal to the Nucleus
MECANISMO DE DOENÇA

Neuronal intranuclear inclusion disease

An autosomal dominant, slowly progressive, neurodegenerative disease characterized by eosinophilic hyaline intranuclear inclusions in the central and peripheral nervous system, and also in the visceral organs. Clinical manifestations are variable and include pyramidal and extrapyramidal symptoms, cerebellar ataxia, cognitive decline and dementia, peripheral neuropathy, and autonomic dysfunction.

INTERAÇÕES PROTEICAS (3)
OUTRAS DOENÇAS (4)
oculopharyngodistal myopathy 3tremor, hereditary essential, 6neuronal intranuclear inclusion diseaseoculopharyngodistal myopathy
HGNC:53924UniProt:P0DPK4
KIF21AKinesin-like protein KIF21ADisease-causing germline mutation(s) inTolerante
FUNÇÃO

Processive microtubule plus-end directed motor protein involved in neuronal axon guidance. Is recruited by KANK1 to cortical microtubule stabilizing complexes (CMSCs) at focal adhesions (FAs) rims where it promotes microtubule capture and stability. Controls microtubule polymerization rate at axonal growth cones and suppresses microtubule growth without inducing microtubule disassembly once it reaches the cell cortex

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCytoplasm, cell cortexCell projection, axonCell projection, dendriteCell projection, growth cone

VIAS BIOLÓGICAS (2)
KinesinsCOPI-dependent Golgi-to-ER retrograde traffic
MECANISMO DE DOENÇA

Fibrosis of extraocular muscles, congenital, 1

A congenital ocular motility disorder marked by restrictive ophthalmoplegia affecting extraocular muscles innervated by the oculomotor and/or trochlear nerves. It is clinically characterized by anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head. Patients affected by congenital fibrosis of extraocular muscles type 1 show an absence of the superior division of the oculomotor nerve (cranial nerve III) and corresponding oculomotor subnuclei.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
44.0 TPM
Cerebelo
34.5 TPM
Brain Frontal Cortex BA9
31.4 TPM
Hipotálamo
25.5 TPM
Brain Spinal cord cervical c-1
23.1 TPM
OUTRAS DOENÇAS (3)
congenital fibrosis of extraocular muscles type 1congenital fibrosis of extraocular musclesfetal akinesia deformation sequence 1
HGNC:19349UniProt:Q7Z4S6
GIPC1PDZ domain-containing protein GIPC1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in G protein-linked signaling

LOCALIZAÇÃO

CytoplasmMembrane

VIAS BIOLÓGICAS (4)
FGFR1b ligand binding and activationFGFR1c ligand binding and activationTGFBR3 regulates FGF2 signalingTGFBR3 regulates TGF-beta signaling
MECANISMO DE DOENÇA

Oculopharyngodistal myopathy 2

A form of oculopharyngodistal myopathy, a muscle disorder characterized by progressive ptosis, external ophthalmoplegia, and weakness of the masseter, facial, pharyngeal, and distal limb muscles. The myopathological features are presence of rimmed vacuoles in the muscle fibers and myopathic changes of differing severity. OPDM2 inheritance pattern is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
340.8 TPM
Vagina
186.9 TPM
Skin Sun Exposed Lower leg
172.1 TPM
Skin Not Sun Exposed Suprapubic
163.3 TPM
Pulmão
111.3 TPM
OUTRAS DOENÇAS (2)
oculopharyngodistal myopathy 2oculopharyngodistal myopathy
HGNC:1226UniProt:O14908
TRAPPC11Trafficking protein particle complex subunit 11Candidate gene tested inTolerante
FUNÇÃO

Involved in endoplasmic reticulum to Golgi apparatus trafficking at a very early stage

LOCALIZAÇÃO

Golgi apparatusGolgi apparatus, cis-Golgi network

VIAS BIOLÓGICAS (1)
RAB GEFs exchange GTP for GDP on RABs
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 18

A form of limb-girdle muscular dystrophy characterized by proximal muscle weakness with childhood onset, resulting in gait abnormalities and scapular winging. Serum creatine kinase is increased. A subset of patients may show a hyperkinetic movement disorder with chorea, ataxia, or dystonia and global developmental delay.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
33.7 TPM
Cérebro - Hemisfério cerebelar
31.5 TPM
Linfócitos
30.9 TPM
Nervo tibial
29.6 TPM
Cerebelo
29.4 TPM
OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type R18intellectual disability-hyperkinetic movement-truncal ataxia syndrometriple-A syndrome
HGNC:25751UniProt:Q7Z392
CAPN3Calpain-3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Calcium-regulated non-lysosomal thiol-protease. Proteolytically cleaves CTBP1 at 'His-409'. Mediates, with UTP25, the proteasome-independent degradation of p53/TP53 (PubMed:23357851, PubMed:27657329)

LOCALIZAÇÃO

CytoplasmNucleus, nucleolus

VIAS BIOLÓGICAS (1)
Degradation of the extracellular matrix
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 1

An autosomal recessive degenerative myopathy characterized by progressive symmetrical atrophy and weakness of the proximal limb muscles and elevated serum creatine kinase. The symptoms usually begin during the first two decades of life, and the disease gradually worsens, often resulting in loss of walking ability 10 or 20 years after onset.

OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type 2Amuscular dystrophy, limb-girdle, autosomal dominant 4autosomal recessive limb-girdle muscular dystrophy
HGNC:1480UniProt:P20807
COL6A2Collagen alpha-2(VI) chainCandidate gene tested inTolerante
FUNÇÃO

Collagen VI acts as a cell-binding protein

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrixMembrane

VIAS BIOLÓGICAS (2)
Collagen biosynthesis and modifying enzymesCollagen chain trimerization
MECANISMO DE DOENÇA

Bethlem myopathy 1B

A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. Inheritance can be autosomal dominant or autosomal recessive.

OUTRAS DOENÇAS (6)
Ullrich congenital muscular dystrophy 1BmyosclerosisBethlem myopathy 1Bintermediate collagen VI-related muscular dystrophy
HGNC:2212UniProt:P12110
TIA1Cytotoxic granule associated RNA binding protein TIA1Candidate gene tested inAltamente restrito
FUNÇÃO

RNA-binding protein involved in the regulation of alternative pre-RNA splicing and mRNA translation by binding to uridine-rich (U-rich) RNA sequences (PubMed:11106748, PubMed:12486009, PubMed:17488725, PubMed:8576255). Binds to U-rich sequences immediately downstream from a 5' splice sites in a uridine-rich small nuclear ribonucleoprotein (U snRNP)-dependent fashion, thereby modulating alternative pre-RNA splicing (PubMed:11106748, PubMed:8576255). Preferably binds to the U-rich IAS1 sequence in

LOCALIZAÇÃO

NucleusCytoplasmCytoplasm, Stress granule

VIAS BIOLÓGICAS (1)
FGFR2 alternative splicing
MECANISMO DE DOENÇA

Welander distal myopathy

An autosomal dominant disorder characterized by adult onset of distal muscle weakness predominantly affecting the distal long extensors of the hands, with slow progression to involve all small hand muscles and the lower legs. Skeletal muscle biopsy shows myopathic changes and prominent rimmed vacuoles. Rare homozygous patients showed earlier onset, faster progression, and proximal muscle involvement.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
112.7 TPM
Cervix Endocervix
105.2 TPM
Útero
102.6 TPM
Cervix Ectocervix
100.3 TPM
Fallopian Tube
98.5 TPM
OUTRAS DOENÇAS (2)
distal myopathy, Welander typeamyotrophic lateral sclerosis 26 with or without frontotemporal dementia
HGNC:11802UniProt:P31483
TMEM43Transmembrane protein 43Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May have an important role in maintaining nuclear envelope structure by organizing protein complexes at the inner nuclear membrane. Required for retaining emerin at the inner nuclear membrane (By similarity). Plays a role in the modulation of innate immune signaling through the cGAS-STING pathway by interacting with RNF26 (PubMed:32614325). In addition, functions as a critical signaling component in mediating NF-kappa-B activation by acting downstream of EGFR and upstream of CARD10 (PubMed:27991

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus inner membraneCell membrane

MECANISMO DE DOENÇA

Arrhythmogenic right ventricular dysplasia, familial, 5

A congenital heart disease characterized by infiltration of adipose and fibrous tissue into the right ventricle and loss of myocardial cells, resulting in ventricular and supraventricular arrhythmias.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
247.5 TPM
Artéria tibial
212.8 TPM
Útero
192.2 TPM
Artéria coronária
180.6 TPM
Fibroblastos
178.4 TPM
OUTRAS DOENÇAS (7)
Emery-Dreifuss muscular dystrophy 7, autosomal dominantarrhythmogenic right ventricular dysplasia 5auditory neuropathy, autosomal dominant 3familial isolated arrhythmogenic ventricular dysplasia, left dominant form
HGNC:28472UniProt:Q9BTV4
SQSTM1Sequestosome-1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Molecular adapter required for selective macroautophagy (aggrephagy) by acting as a bridge between polyubiquitinated proteins and autophagosomes (PubMed:15340068, PubMed:15953362, PubMed:16286508, PubMed:17580304, PubMed:20168092, PubMed:22017874, PubMed:22622177, PubMed:24128730, PubMed:28404643, PubMed:29343546, PubMed:29507397, PubMed:31857589, PubMed:33509017, PubMed:34471133, PubMed:34893540, PubMed:35831301, PubMed:37306101, PubMed:37802024). Promotes the recruitment of ubiquitinated cargo

LOCALIZAÇÃO

Cytoplasmic vesicle, autophagosomePreautophagosomal structureCytoplasm, cytosolNucleus, PML bodyLate endosomeLysosomeNucleusEndoplasmic reticulumCytoplasm, myofibril, sarcomere

VIAS BIOLÓGICAS (9)
PINK1-PRKN Mediated MitophagyPexophagyNF-kB is activated and signals survivalp75NTR recruits signalling complexesInterleukin-1 signaling
MECANISMO DE DOENÇA

Paget disease of bone 3

A disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal adult lamellar bone.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
155.2 TPM
Artéria tibial
140.4 TPM
Aorta
135.6 TPM
Fibroblastos
134.0 TPM
Glândula adrenal
131.3 TPM
OUTRAS DOENÇAS (8)
Paget disease of bone 3myopathy, distal, with rimmed vacuolesneurodegeneration with ataxia, dystonia, and gaze palsy, childhood-onsetfrontotemporal dementia and/or amyotrophic lateral sclerosis 3
HGNC:11280UniProt:Q13501
MYOTMyotilinCandidate gene tested inTolerante
FUNÇÃO

Component of a complex of multiple actin cross-linking proteins. Involved in the control of myofibril assembly and stability at the Z lines in muscle cells

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeletonCytoplasm, myofibril, sarcomere, Z line

MECANISMO DE DOENÇA

Myopathy, myofibrillar, 3

A form of myofibrillar myopathy, a group of chronic neuromuscular disorders characterized at ultrastructural level by disintegration of the sarcomeric Z disk and myofibrils, and replacement of the normal myofibrillar markings by small dense granules, or larger hyaline masses, or amorphous material. MFM3 is characterized by progressive skeletal muscle weakness greater distally than proximally, tight heel cords, hyporeflexia, cardiomyopathy and peripheral neuropathy in some patients. Affected muscle exhibits disorganization and streaming of the Z-line, presence of large hyaline structures, excessive accumulation of myotilin and other ectopically expressed proteins and prominent congophilic deposits.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
602.6 TPM
Nervo tibial
12.9 TPM
Cólon sigmoide
10.7 TPM
Cervix Ectocervix
9.3 TPM
Esôfago - Muscular
9.1 TPM
OUTRAS DOENÇAS (1)
myofibrillar myopathy 3
HGNC:12399UniProt:Q9UBF9
CRPPAD-ribitol-5-phosphate cytidylyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Cytidylyltransferase required for protein O-linked mannosylation (PubMed:22522420, PubMed:22522421, PubMed:26687144, PubMed:26923585, PubMed:27130732, PubMed:27601598). Catalyzes the formation of CDP-ribitol nucleotide sugar from D-ribitol 5-phosphate (PubMed:26687144, PubMed:26923585, PubMed:27130732). CDP-ribitol is a substrate of FKTN during the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carboh

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A7

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Umuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7muscle-eye-brain diseasemuscular dystrophy-dystroglycanopathy, type A
HGNC:37276UniProt:A4D126
POMT2Protein O-mannosyl-transferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Regulation of CDH1 posttranslational processing and trafficking to plasma membraneDAG1 core M1 glycosylationsDAG1 core M3 glycosylationsDAG1 core M2 glycosylationsDefective POMT1 causes MDDGA1, MDDGB1 and MDDGC1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A2

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
59.9 TPM
Pituitária
28.9 TPM
Tireoide
27.7 TPM
Cervix Endocervix
21.2 TPM
Cerebelo
21.2 TPM
OUTRAS DOENÇAS (7)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A2muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B2autosomal recessive limb-girdle muscular dystrophy type 2Nmuscle-eye-brain disease
HGNC:19743UniProt:Q9UKY4
SGCBBeta-sarcoglycanDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 4

An autosomal recessive degenerative myopathy characterized by pelvic and shoulder muscle wasting, onset usually in childhood and variable progression rate.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
100.8 TPM
Aorta
89.2 TPM
Artéria tibial
80.8 TPM
Artéria coronária
72.2 TPM
Fibroblastos
69.7 TPM
OUTRAS DOENÇAS (2)
autosomal recessive limb-girdle muscular dystrophy type 2Eautosomal recessive limb-girdle muscular dystrophy
HGNC:10806UniProt:Q16585
CRYABAlpha-crystallin B chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

May contribute to the transparency and refractive index of the lens. Has chaperone-like activity, preventing aggregation of various proteins under a wide range of stress conditions. In lens epithelial cells, stabilizes the ATP6V1A protein, preventing its degradation by the proteasome (By similarity)

LOCALIZAÇÃO

CytoplasmNucleusSecretedLysosome

VIAS BIOLÓGICAS (1)
HSF1-dependent transactivation
MECANISMO DE DOENÇA

Myopathy, myofibrillar, 2A, adult-onset

A form of myofibrillar myopathy, a group of chronic neuromuscular disorders characterized at ultrastructural level by disintegration of the sarcomeric Z disk and myofibrils, and replacement of the normal myofibrillar markings by small dense granules, or larger hyaline masses, or amorphous material. MFM2A is an autosomal dominant form characterized by weakness of the proximal and distal limb muscles, weakness of the neck, velopharynx and trunk muscles, respiratory insufficiency, hypertrophic cardiomyopathy, and cataract.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
1863.3 TPM
Brain Spinal cord cervical c-1
1663.2 TPM
Coração - Átrio
1591.1 TPM
Músculo esquelético
1435.1 TPM
Nervo tibial
1093.8 TPM
OUTRAS DOENÇAS (8)
fatal infantile hypertonic myofibrillar myopathymyofibrillar myopathy 2dilated cardiomyopathy 1IIcataract 16 multiple types
HGNC:2389UniProt:P02511
INPP5KInositol polyphosphate 5-phosphatase KDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Inositol 5-phosphatase which acts on inositol 1,4,5-trisphosphate, inositol 1,3,4,5-tetrakisphosphate, phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate (PubMed:10753883, PubMed:16824732). Has 6-fold higher affinity for phosphatidylinositol 4,5-bisphosphate than for inositol 1,4,5-trisphosphate (PubMed:10753883). Negatively regulates assembly of the actin cytoskeleton. Controls insulin-dependent glucose uptake among inositol 3,4,5-trisphosphate phosphatases; ther

LOCALIZAÇÃO

Endoplasmic reticulumCytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of PIPs at the plasma membrane
MECANISMO DE DOENÇA

Muscular dystrophy, congenital, with cataracts and impaired intellectual development

An autosomal recessive form of muscular dystrophy with onset in early childhood and characterized by progressive muscle weakness. Almost all patients also have early-onset cataracts and intellectual disability of varying severity. Some patients have seizures.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
62.3 TPM
Testículo
54.3 TPM
Nervo tibial
52.9 TPM
Tecido adiposo
51.7 TPM
Pulmão
51.4 TPM
OUTRAS DOENÇAS (1)
congenital muscular dystrophy with cataracts and intellectual disability
HGNC:33882UniProt:Q9BT40
POMKProtein O-mannose kinaseCandidate gene tested inTolerante
FUNÇÃO

Protein O-mannose kinase that specifically mediates phosphorylation at the 6-position of an O-mannose of the trisaccharide (N-acetylgalactosamine (GalNAc)-beta-1,3-N-acetylglucosamine (GlcNAc)-beta-1,4-mannose) to generate phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-1,3-N-acetylglucosamine-beta-1,4-(phosphate-6-)mannose). Phosphorylated O-mannosyl trisaccharide is a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like d

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A12

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
6.4 TPM
Fibroblastos
5.9 TPM
Cérebro - Hemisfério cerebelar
3.0 TPM
Cerebelo
2.7 TPM
Testículo
2.3 TPM
OUTRAS DOENÇAS (4)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 12limb-girdle muscular dystrophy due to POMK deficiencyobsolete congenital muscular dystrophy with cerebellar involvementmuscular dystrophy-dystroglycanopathy, type A
HGNC:26267UniProt:Q9H5K3
CAV3Caveolin-3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity. May also regulate voltage-gated potassium channels. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress (By similarity). Mediates the recruitment of CAVIN2 and CAVIN3 proteins to the caveolae (PubMed:19262564)

LOCALIZAÇÃO

Golgi apparatus membraneCell membraneMembrane, caveolaCell membrane, sarcolemma

VIAS BIOLÓGICAS (1)
Smooth Muscle Contraction
MECANISMO DE DOENÇA

HyperCKmia

Characterized by persistent elevated levels of serum creatine kinase without muscle weakness.

OUTRAS DOENÇAS (7)
rippling muscle disease 2distal myopathy, Tateyama typelong QT syndrome 9creatine phosphokinase, elevated serum
HGNC:1529UniProt:P56539
LAMA2Laminin subunit alpha-2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other extracellular matrix components

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membrane

VIAS BIOLÓGICAS (8)
MET activates PTK2 signalingDevelopmental Lineage of Pancreatic Ductal CellsAttachment of bacteria to epithelial cellsLaminin interactionsEGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Merosin-deficient congenital muscular dystrophy 1A

Characterized by difficulty walking, hypotonia, proximal weakness, hyporeflexia, and white matter hypodensity on MRI.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
116.5 TPM
Nervo tibial
92.9 TPM
Fallopian Tube
80.1 TPM
Artéria coronária
63.2 TPM
Fibroblastos
62.6 TPM
OUTRAS DOENÇAS (2)
congenital merosin-deficient muscular dystrophy 1Amuscular dystrophy, limb-girdle, autosomal recessive 23
HGNC:6482UniProt:P24043
COL6A3Collagen alpha-3(VI) chainCandidate gene tested inRestrito
FUNÇÃO

Collagen VI acts as a cell-binding protein

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (1)
Collagen degradation
MECANISMO DE DOENÇA

Bethlem myopathy 1C

A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. BTHLM1C inheritance is autosomal dominant.

OUTRAS DOENÇAS (6)
dystonia 27Ullrich congenital muscular dystrophy 1CBethlem myopathy 1Cintermediate collagen VI-related muscular dystrophy
HGNC:2213UniProt:P12111
FHL1Four and a half LIM domains protein 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

May have an involvement in muscle development or hypertrophy

LOCALIZAÇÃO

CytoplasmNucleusCytoplasm, cytosol

MECANISMO DE DOENÇA

Emery-Dreifuss muscular dystrophy 6, X-linked

A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
2024.8 TPM
Artéria tibial
1151.4 TPM
Aorta
1150.7 TPM
Esôfago - Junção
873.7 TPM
Esôfago - Muscular
862.0 TPM
OUTRAS DOENÇAS (7)
X-linked myopathy with postural muscle atrophyX-linked scapuloperoneal muscular dystrophymyopathy, reducing body, X-linked, early-onset, severemyopathy, reducing body, X-linked, childhood-onset
HGNC:3702UniProt:Q13642
CNBPCCHC-type zinc finger nucleic acid binding proteinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Single-stranded DNA-binding protein that preferentially binds to the sterol regulatory element (SRE) sequence 5'-GTGCGGTG-3', and thereby mediates transcriptional repression (PubMed:2562787). Has a role as transactivator of the Myc promoter (By similarity). Binds single-stranded RNA in a sequence-specific manner (By similarity) Binds G-rich elements in target mRNA coding sequences (PubMed:28329689). Prevents G-quadruplex structure formation in vitro, suggesting a role in supporting translation b

LOCALIZAÇÃO

NucleusCytoplasmEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
SARS-CoV-2 activates/modulates innate and adaptive immune responses
MECANISMO DE DOENÇA

Dystrophia myotonica 2

A multisystem disease characterized by the association of proximal muscle weakness with myotonia, cardiac manifestations and cataract. Additional features can include hyperhidrosis, testicular atrophy, insulin resistance and diabetes and central nervous system anomalies in rare cases.

OUTRAS DOENÇAS (1)
myotonic dystrophy type 2
HGNC:13164UniProt:P62633
POMGNT2Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

O-linked mannose beta-1,4-N-acetylglucosaminyltransferase that transfers UDP-N-acetyl-D-glucosamine to the 4-position of the mannose to generate N-acetyl-D-glucosamine-beta-1,4-O-D-mannosylprotein. Involved in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for binding laminin G-like domain-containing extracellular prote

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A8

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
98.5 TPM
Cerebelo
94.9 TPM
Cérebro - Hemisfério cerebelar
94.0 TPM
Ovário
60.0 TPM
Fallopian Tube
58.8 TPM
OUTRAS DOENÇAS (3)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 8muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 8muscular dystrophy-dystroglycanopathy, type A
HGNC:25902UniProt:Q8NAT1
DAG1Dystroglycan 1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

The dystroglycan complex is involved in a number of signaling events and processes including laminin deposition and extracellular matrix assembly, acetylcholine receptor clustering, sarcolemmal stability, cell survival, peripheral nerve myelination, nodal structure, cell migration, epithelial polarization, and epithelium branching morphogenesis (By similarity). Required for the formation of photoreceptor ribbon synapses, and long-term maintenance of inhibitory synapses in cerebellar Purkinje cel

LOCALIZAÇÃO

Secreted, extracellular spaceSecreted, extracellular space, extracellular matrix, basement membraneSynapseCell membraneCytoplasm, cytoskeletonNucleus, nucleoplasmCell membrane, sarcolemmaPostsynaptic cell membrane

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy limb-girdle C9

An autosomal recessive muscular dystrophy showing onset in early childhood, and associated with intellectual disability without structural brain anomalies.

EXPRESSÃO TECIDUAL(Ubíquo)
Nervo tibial
118.7 TPM
Artéria tibial
71.1 TPM
Aorta
69.5 TPM
Esôfago - Muscular
66.9 TPM
Esôfago - Junção
64.7 TPM
OUTRAS DOENÇAS (5)
autosomal recessive limb-girdle muscular dystrophy type 2Pmuscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A9isolated asymptomatic elevation of creatine phosphokinasemuscular dystrophy-dystroglycanopathy, type A
HGNC:2666UniProt:Q14118
PHOX2APaired mesoderm homeobox protein 2ADisease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in regulating the specificity of expression of the catecholamine biosynthetic genes. Acts as a transcription activator/factor. Could maintain the noradrenergic phenotype

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Fibrosis of extraocular muscles, congenital, 2

A congenital ocular motility disorder marked by restrictive ophthalmoplegia affecting extraocular muscles innervated by the oculomotor and/or trochlear nerves. It is clinically characterized by anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head. Congenital fibrosis of extraocular muscles type 2 may result from the defective development of the oculomotor (nIII), trochlear (nIV) and abducens (nVI) cranial nerve nuclei.

EXPRESSÃO TECIDUAL(Baixa expressão)
Cólon sigmoide
2.7 TPM
Testículo
1.4 TPM
Esôfago - Muscular
1.4 TPM
Cólon transverso
1.3 TPM
Esôfago - Junção
1.0 TPM
OUTRAS DOENÇAS (2)
fibrosis of extraocular muscles, congenital, 2congenital fibrosis of extraocular muscles
HGNC:691UniProt:O14813
LRP12Low-density lipoprotein receptor-related protein 12Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Probable receptor, which may be involved in the internalization of lipophilic molecules and/or signal transduction. May act as a tumor suppressor

LOCALIZAÇÃO

MembraneMembrane, coated pit

VIAS BIOLÓGICAS (1)
Retinoid metabolism and transport
MECANISMO DE DOENÇA

Oculopharyngodistal myopathy 1

A form of oculopharyngodistal myopathy, a muscle disorder characterized by progressive ptosis, external ophthalmoplegia, and weakness of the masseter, facial, pharyngeal, and distal limb muscles. The myopathological features are presence of rimmed vacuoles in the muscle fibers and myopathic changes of differing severity. OPDM1 inheritance pattern is autosomal dominant.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
21.3 TPM
Útero
17.0 TPM
Artéria tibial
10.5 TPM
Fallopian Tube
10.3 TPM
Aorta
9.5 TPM
INTERAÇÕES PROTEICAS (1)
OUTRAS DOENÇAS (3)
oculopharyngodistal myopathy 1amyotrophic lateral sclerosis 28oculopharyngodistal myopathy
HGNC:31708UniProt:Q9Y561
MYH7Myosin-7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Myosins are actin-based motor molecules with ATPase activity essential for muscle contraction. Forms regular bipolar thick filaments that, together with actin thin filaments, constitute the fundamental contractile unit of skeletal and cardiac muscle

LOCALIZAÇÃO

Cytoplasm, myofibrilCytoplasm, myofibril, sarcomere

MECANISMO DE DOENÇA

Cardiomyopathy, familial hypertrophic, 1

A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
4513.7 TPM
Músculo esquelético
3692.8 TPM
Coração - Átrio
592.2 TPM
Pâncreas
5.3 TPM
Hipotálamo
4.9 TPM
OUTRAS DOENÇAS (12)
MYH7-related skeletal myopathymyopathy, myosin storage, autosomal recessivedilated cardiomyopathy 1Scongenital myopathy 7A, myosin storage, autosomal dominant
HGNC:7577UniProt:P12883
HNRNPA2B1Heterogeneous nuclear ribonucleoproteins A2/B1Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Heterogeneous nuclear ribonucleoprotein (hnRNP) that associates with nascent pre-mRNAs, packaging them into hnRNP particles. The hnRNP particle arrangement on nascent hnRNA is non-random and sequence-dependent and serves to condense and stabilize the transcripts and minimize tangling and knotting. Packaging plays a role in various processes such as transcription, pre-mRNA processing, RNA nuclear export, subcellular location, mRNA translation and stability of mature mRNAs (PubMed:19099192). Forms

LOCALIZAÇÃO

NucleusNucleus, nucleoplasmCytoplasmCytoplasmic granuleSecreted, extracellular exosome

VIAS BIOLÓGICAS (1)
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
MECANISMO DE DOENÇA

Inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2

An autosomal dominant disease characterized by disabling muscle weakness clinically resembling to limb girdle muscular dystrophy, osteolytic bone lesions consistent with Paget disease, and premature frontotemporal dementia. Clinical features show incomplete penetrance.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
889.4 TPM
Linfócitos
838.4 TPM
Útero
763.3 TPM
Cervix Endocervix
691.2 TPM
Cervix Ectocervix
681.9 TPM
OUTRAS DOENÇAS (3)
oculopharyngeal muscular dystrophy 2inclusion body myopathy with early-onset Paget disease with or without frontotemporal dementia 2inclusion body myopathy with Paget disease of bone and frontotemporal dementia
HGNC:5033UniProt:P22626
GMPPBMannose-1-phosphate guanylyltransferase catalytic subunit betaDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the GMPPA-GMPPB mannose-1-phosphate guanylyltransferase complex (PubMed:33986552). Catalyzes the formation of GDP-mannose, an essential precursor of glycan moieties of glycoproteins and glycolipids (PubMed:33986552). Can catalyze the reverse reaction in vitro (PubMed:33986552). Together with GMPPA regulates GDP-alpha-D-mannose levels (PubMed:33986552)

LOCALIZAÇÃO

Cytoplasm

VIAS BIOLÓGICAS (1)
Synthesis of GDP-mannose
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A14

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with brain anomalies, eye malformations, and profound intellectual disability. The disorder includes a severe form designated as Walker-Warburg syndrome and a less severe phenotype known as muscle-eye-brain disease. MDDGA14 features include increased muscle tone, microcephaly, cleft palate, feeding difficulties, severe muscle weakness, sensorineural hearing loss, cerebellar hypoplasia, ataxia, and retinal dysfunction.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
56.4 TPM
Tireoide
41.5 TPM
Linfócitos
39.6 TPM
Próstata
37.0 TPM
Glândula salivar
32.5 TPM
OUTRAS DOENÇAS (7)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A14autosomal recessive limb-girdle muscular dystrophy type 2Tmuscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B14muscle-eye-brain disease
HGNC:22932UniProt:Q9Y5P6
COL6A1Collagen alpha-1(VI) chainCandidate gene tested inTolerante
FUNÇÃO

Collagen VI acts as a cell-binding protein

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (2)
Collagen biosynthesis and modifying enzymesCollagen chain trimerization
MECANISMO DE DOENÇA

Bethlem myopathy 1A

A form of Bethlem myopathy, a slowly progressive muscular dystrophy characterized by joint contractures, most frequently affecting the elbows and ankles, and muscle weakness and wasting involving the proximal and extensor muscles more than the distal and flexor ones. The clinical onset more often occurs in childhood or adulthood, but it can be prenatal with decreased fetal movements or neonatal with hypotonia. The hallmark of Bethlem myopathy is long finger flexion contractures. Inheritance can be autosomal dominant or autosomal recessive.

OUTRAS DOENÇAS (5)
Ullrich congenital muscular dystrophy 1ABethlem myopathy 1Aintermediate collagen VI-related muscular dystrophyBethlem myopathy
HGNC:2211UniProt:P12109
SGCDDelta-sarcoglycanDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 6

An autosomal recessive degenerative myopathy initially affecting the proximal limb girdle musculature. Muscle from patients shows a complete loss of delta-sarcoglycan as well as of the others components of the sarcoglycan complex.

EXPRESSÃO TECIDUAL(Ubíquo)
Artéria tibial
26.6 TPM
Aorta
20.2 TPM
Músculo esquelético
15.2 TPM
Esôfago - Junção
14.2 TPM
Coração - Átrio
12.8 TPM
OUTRAS DOENÇAS (4)
autosomal recessive limb-girdle muscular dystrophy type 2Fdilated cardiomyopathy 1Lautosomal recessive limb-girdle muscular dystrophyfamilial isolated dilated cardiomyopathy
HGNC:10807UniProt:Q92629
SELENONSelenoprotein NCandidate gene tested inTolerante
FUNÇÃO

Plays an important role in cell protection against oxidative stress and in the regulation of redox-related calcium homeostasis. Regulates the calcium level of the ER by protecting the calcium pump ATP2A2 against the oxidoreductase ERO1A-mediated oxidative damage. Within the ER, ERO1A activity increases the concentration of H(2)O(2), which attacks the luminal thiols in ATP2A2 and thus leads to cysteinyl sulfenic acid formation (-SOH) and SEPN1 reduces the SOH back to free thiol (-SH), thus restor

LOCALIZAÇÃO

Endoplasmic reticulum membrane

MECANISMO DE DOENÇA

Congenital myopathy 3 with rigid spine

An autosomal recessive, slowly progressive muscular disorder apparent from birth or early childhood and characterized by hypotonia, proximal muscle weakness, poor axial muscle strength, scoliosis and neck weakness, and a variable degree of spinal rigidity. Most patients remain ambulatory. Early ventilatory insufficiency may lead to death by respiratory failure. Additional features may include facial muscle weakness, amyotrophy, joint contractures, distal hyperlaxity, pulmonary hypertension with secondary cardiac dysfunction, and insulin resistance in patients with a low BMI. Skeletal muscle biopsy typically shows multiminicores and other abnormal non-specific myopathic findings.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
167.2 TPM
Tireoide
103.6 TPM
Útero
101.6 TPM
Ovário
95.0 TPM
Mama
92.8 TPM
OUTRAS DOENÇAS (5)
rigid spine muscular dystrophy 1congenital fiber-type disproportion myopathydesmin-related myopathy with Mallory body-like inclusionsclassic multiminicore myopathy
HGNC:15999UniProt:Q9NZV5
SGCAAlpha-sarcoglycanCandidate gene tested inTolerante
FUNÇÃO

Component of the sarcoglycan complex, a subcomplex of the dystrophin-glycoprotein complex which forms a link between the F-actin cytoskeleton and the extracellular matrix

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasm, cytoskeleton

VIAS BIOLÓGICAS (1)
Formation of the dystrophin-glycoprotein complex (DGC)
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 3

An autosomal recessive degenerative myopathy characterized by progressive muscle wasting from early childhood with loss of independent ambulation by teenage years. Muscle biopsy shows necrosis, decreased immunostaining for alpha sarcoglycan, and adhalin deficiency.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
227.0 TPM
Aorta
223.0 TPM
Artéria tibial
162.2 TPM
Artéria coronária
146.7 TPM
Esôfago - Junção
94.6 TPM
OUTRAS DOENÇAS (2)
autosomal recessive limb-girdle muscular dystrophyautosomal recessive limb-girdle muscular dystrophy type 2D
HGNC:10805UniProt:Q16586
TNPO3Transportin-3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Importin, which transports target proteins into the nucleus (PubMed:10366588, PubMed:10713112, PubMed:11517331, PubMed:12628928, PubMed:24449914). Specifically mediates the nuclear import of splicing factor serine/arginine (SR) proteins, such as RBM4, SFRS1 and SFRS2, by recognizing phosphorylated SR domains (PubMed:10366588, PubMed:10713112, PubMed:11517331, PubMed:12628928, PubMed:24449914). Also mediates the nuclear import of serine/arginine (SR) protein CPSF6, independently of CPSF6 phosphor

LOCALIZAÇÃO

Nucleus envelopeCytoplasm

MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal dominant 2

An autosomal dominant myopathy characterized by proximal muscle weakness primarily affecting the lower limbs, but also affecting the upper limbs in most patients. Affected individuals also have distal muscle weakness of the hands and lower leg muscles. The disease has generally a benign clinical course but some individuals with childhood or juvenile onset manifest severe widespread myopathy, leading to wheelchair dependency and respiratory insufficiency. Muscle biopsy shows dystrophic changes with abnormal nuclei, rimmed vacuoles, and filamentous inclusions.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
79.5 TPM
Fibroblastos
47.6 TPM
Testículo
40.2 TPM
Cérebro - Hemisfério cerebelar
35.1 TPM
Ovário
32.1 TPM
OUTRAS DOENÇAS (2)
autosomal dominant limb-girdle muscular dystrophy type 1Fprimary biliary cholangitis
HGNC:17103UniProt:Q9Y5L0
LMNAPrelamin-A/CCandidate gene tested inAltamente restrito
FUNÇÃO

Lamins are intermediate filament proteins that assemble into a filamentous meshwork, and which constitute the major components of the nuclear lamina, a fibrous layer on the nucleoplasmic side of the inner nuclear membrane (PubMed:10080180, PubMed:10580070, PubMed:10587585, PubMed:10814726, PubMed:11799477, PubMed:12075506, PubMed:12927431, PubMed:15317753, PubMed:18551513, PubMed:18611980, PubMed:2188730, PubMed:22431096, PubMed:2344612, PubMed:23666920, PubMed:24741066, PubMed:31434876, PubMed:

LOCALIZAÇÃO

Nucleus laminaNucleus envelopeNucleus, nucleoplasmNucleus matrixNucleus speckle

VIAS BIOLÓGICAS (1)
Initiation of Nuclear Envelope (NE) Reformation
MECANISMO DE DOENÇA

Emery-Dreifuss muscular dystrophy 2, autosomal dominant

A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
392.7 TPM
Aorta
300.6 TPM
Skin Not Sun Exposed Suprapubic
297.7 TPM
Skin Sun Exposed Lower leg
272.6 TPM
Útero
255.8 TPM
OUTRAS DOENÇAS (23)
restrictive dermopathy 2familial partial lipodystrophy, Dunnigan typedilated cardiomyopathy-hypergonadotropic hypogonadism syndromemandibuloacral dysplasia with type A lipodystrophy
HGNC:6636UniProt:P02545
HMGCR3-hydroxy-3-methylglutaryl-coenzyme A reductaseCandidate gene tested inAltamente restrito
FUNÇÃO

Catalyzes the conversion of (3S)-hydroxy-3-methylglutaryl-CoA (HMG-CoA) to mevalonic acid, the rate-limiting step in the synthesis of cholesterol and other isoprenoids, thus plays a critical role in cellular cholesterol homeostasis (PubMed:21357570, PubMed:2991281, PubMed:36745799, PubMed:6995544). HMGCR is the main target of statins, a class of cholesterol-lowering drugs (PubMed:11349148, PubMed:18540668, PubMed:36745799)

LOCALIZAÇÃO

Endoplasmic reticulum membranePeroxisome membrane

VIAS BIOLÓGICAS (1)
EGR2 and SOX10-mediated initiation of Schwann cell myelination
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 28

An autosomal recessive form of limb girdle muscular dystrophy, a group of genetically heterogeneous muscular disorders that share proximal muscle weakness as the major attribute. Most limb girdle muscular dystrophies present with elevated creatinine kinase and myopathic electromyographic features. Disease is usually progressive to a variable degree, ranging from minor disability to complete inability to ambulate, and can involve the large proximal muscles, as well as axial and facial muscles. Different disease forms may exhibit skeletal muscle hypertrophy, kyphoscoliosis, and contractures or involve other muscle groups and manifest with distal weakness, cardiomyopathy, dysphagia, and respiratory difficulties. LGMDR28 is characterized by progressive muscle weakness affecting the proximal and axial muscles of the upper and lower limbs, and highly variable age at onset. Most patients have limited ambulation or become wheelchair-bound within a few decades, and respiratory insufficiency commonly occurs.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Not Sun Exposed Suprapubic
80.4 TPM
Skin Sun Exposed Lower leg
73.8 TPM
Linfócitos
66.2 TPM
Esôfago - Mucosa
63.8 TPM
Vagina
42.9 TPM
OUTRAS DOENÇAS (1)
muscular dystrophy, limb-girdle, autosomal recessive 28
HGNC:5006UniProt:P04035
MATR3Matrin-3Candidate gene tested inAltamente restrito
FUNÇÃO

May play a role in transcription or may interact with other nuclear matrix proteins to form the internal fibrogranular network. In association with the SFPQ-NONO heteromer may play a role in nuclear retention of defective RNAs. Plays a role in the regulation of DNA virus-mediated innate immune response by assembling into the HDP-RNP complex, a complex that serves as a platform for IRF3 phosphorylation and subsequent innate immune response activation through the cGAS-STING pathway (PubMed:2871272

LOCALIZAÇÃO

Nucleus matrix

MECANISMO DE DOENÇA

Amyotrophic lateral sclerosis 21

A neurodegenerative disorder affecting upper and lower motor neurons, resulting in muscle weakness and respiratory failure. Some patients may develop myopathic features or dementia.

OUTRAS DOENÇAS (3)
amyotrophic lateral sclerosis type 21distal myopathy with vocal cord weaknessamyotrophic lateral sclerosis
HGNC:6912UniProt:P43243
ANO5Anoctamin-5Candidate gene tested inTolerante
FUNÇÃO

Plays a role in plasma membrane repair in a process involving annexins (PubMed:33496727). Does not exhibit calcium-activated chloride channel (CaCC) activity

LOCALIZAÇÃO

Endoplasmic reticulum membraneCell membrane

VIAS BIOLÓGICAS (2)
Induction of Cell-Cell FusionStimuli-sensing channels
MECANISMO DE DOENÇA

Gnathodiaphyseal dysplasia

Rare skeletal syndrome characterized by bone fragility, sclerosis of tubular bones, and cemento-osseous lesions of the jawbone. Patients experience frequent bone fractures caused by trivial accidents in childhood; however the fractures heal normally without bone deformity. The jaw lesions replace the tooth-bearing segments of the maxilla and mandible with fibrous connective tissues, including various amounts of cementum-like calcified mass, sometimes causing facial deformities. Patients also have a propensity for jaw infection and often suffer from purulent osteomyelitis-like symptoms, such as swelling of and pus discharge from the gums, mobility of the teeth, insufficient healing after tooth extraction and exposure of the lesions into the oral cavity.

OUTRAS DOENÇAS (6)
autosomal recessive limb-girdle muscular dystrophy type 2Lgnathodiaphyseal dysplasiaautosomal recessive limb-girdle muscular dystrophyMiyoshi muscular dystrophy 3
HGNC:27337UniProt:Q75V66
DNMT3BDNA (cytosine-5)-methyltransferase 3BDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Required for genome-wide de novo methylation and is essential for the establishment of DNA methylation patterns during development. DNA methylation is coordinated with methylation of histones. May preferentially methylates nucleosomal DNA within the nucleosome core region. May function as transcriptional co-repressor by associating with CBX4 and independently of DNA methylation. Seems to be involved in gene silencing (By similarity). In association with DNMT1 and via the recruitment of CTCFL/BOR

LOCALIZAÇÃO

Nucleus

VIAS BIOLÓGICAS (5)
Defective pyroptosisPRC2 methylates histones and DNADNA methylationNoRC negatively regulates rRNA expressionSUMOylation of DNA methylation proteins
MECANISMO DE DOENÇA

Immunodeficiency-centromeric instability-facial anomalies syndrome 1

A rare disorder characterized by a variable immunodeficiency resulting in recurrent infections, facial anomalies, and branching of chromosomes 1, 9, and 16. Other variable symptoms include growth retardation, failure to thrive, and psychomotor retardation. Laboratory studies show limited hypomethylation of DNA in a small fraction of the genome in some, but not all, patients.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
12.8 TPM
Cerebelo
5.4 TPM
Cérebro - Hemisfério cerebelar
5.3 TPM
Skin Sun Exposed Lower leg
5.1 TPM
Skin Not Sun Exposed Suprapubic
4.9 TPM
OUTRAS DOENÇAS (4)
facioscapulohumeral muscular dystrophy 4, digenicimmunodeficiency-centromeric instability-facial anomalies syndrome 1immunodeficiency-centromeric instability-facial anomalies syndromefacioscapulohumeral muscular dystrophy
HGNC:2979UniProt:Q9UBC3
B4GAT1Beta-1,4-glucuronyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Beta-1,4-glucuronyltransferase involved in O-mannosylation of alpha-dystroglycan (DAG1) (PubMed:19587235, PubMed:23359570, PubMed:25279697, PubMed:25279699). Transfers a glucuronic acid (GlcA) residue onto a xylose (Xyl) acceptor to produce the glucuronyl-beta-1,4-xylose-beta disaccharide primer, which is further elongated by LARGE1, during synthesis of phosphorylated O-mannosyl glycan (PubMed:25279697, PubMed:25279699). Phosphorylated O-mannosyl glycan is a carbohydrate structure present in alp

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (3)
Keratan sulfate biosynthesisMatriglycan biosynthesis on DAG1Defective LARGE causes MDDGA6 and MDDGB6
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A13

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (2)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A13muscular dystrophy-dystroglycanopathy, type A
HGNC:15685UniProt:O43505
POMT1Protein O-mannosyl-transferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. Coexpression of both POMT1 and POMT2 is necessary for enzyme activity, expression of either POMT1 or POMT2 alone is insufficient (PubMed:12369018, PubMed:14699049, PubMed:28512129). Essentially dedicated to O-mannosylation of alpha-DAG1 and few other proteins but not of cadherins and protocaherins (PubMed:28512129)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Regulation of CDH1 posttranslational processing and trafficking to plasma membraneDAG1 core M1 glycosylationsDAG1 core M3 glycosylationsDAG1 core M2 glycosylationsDefective POMT2 causes MDDGA2, MDDGB2 and MDDGC2
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B1

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with intellectual disability and mild structural brain abnormalities.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
73.9 TPM
Cerebelo
65.0 TPM
Cérebro - Hemisfério cerebelar
61.3 TPM
Pituitária
32.9 TPM
Ovário
27.8 TPM
OUTRAS DOENÇAS (8)
autosomal recessive limb-girdle muscular dystrophy type 2Kmuscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A1muscle-eye-brain disease
HGNC:9202UniProt:Q9Y6A1
RXYLT1Ribitol-5-phosphate xylosyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Acts as a UDP-D-xylose:ribitol-5-phosphate beta1,4-xylosyltransferase, which catalyzes the transfer of UDP-D-xylose to ribitol 5-phosphate (Rbo5P) to form the Xylbeta1-4Rbo5P linkage on O-mannosyl glycan (Probable) (PubMed:27733679, PubMed:29477842). Participates in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1), which is required for bin

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A10

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (2)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 10muscular dystrophy-dystroglycanopathy, type A
HGNC:13530UniProt:Q9Y2B1
FKRPRibitol 5-phosphate transferase FKRPDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the transfer of a ribitol 5-phosphate from CDP-L-ribitol to the ribitol 5-phosphate previously attached by FKTN/fukutin to the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1) (PubMed:26923585, PubMed:27194101, PubMed:29477842, PubMed:31949166). This constitutes the second step in the formation of the ribose 5-phosphate tandem repeat which links the phos

LOCALIZAÇÃO

Golgi apparatus membraneSecretedCell membrane, sarcolemmaRough endoplasmic reticulumCytoplasm

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A5

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
19.7 TPM
Útero
18.0 TPM
Fibroblastos
17.7 TPM
Tireoide
16.6 TPM
Fallopian Tube
16.5 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A5muscular dystrophy-dystroglycanopathy type B5autosomal recessive limb-girdle muscular dystrophy type 2Imuscle-eye-brain disease
HGNC:17997UniProt:Q9H9S5
DMPKMyotonin-protein kinaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Non-receptor serine/threonine protein kinase which is necessary for the maintenance of skeletal muscle structure and function. May play a role in myocyte differentiation and survival by regulating the integrity of the nuclear envelope and the expression of muscle-specific genes. May also phosphorylate PPP1R12A and inhibit the myosin phosphatase activity to regulate myosin phosphorylation. Also critical to the modulation of cardiac contractility and to the maintenance of proper cardiac conduction

LOCALIZAÇÃO

Endoplasmic reticulum membraneNucleus outer membraneMitochondrion outer membraneSarcoplasmic reticulum membraneCell membraneCytoplasm, cytosolMitochondrion membrane

VIAS BIOLÓGICAS (1)
Ion homeostasis
MECANISMO DE DOENÇA

Dystrophia myotonica 1

A muscular disorder characterized by myotonia, muscle wasting in the distal extremities, cataract, hypogonadism, defective endocrine functions, male baldness and cardiac arrhythmias.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Junção
258.6 TPM
Esôfago - Muscular
241.8 TPM
Artéria tibial
229.7 TPM
Aorta
207.1 TPM
Cólon sigmoide
195.1 TPM
OUTRAS DOENÇAS (6)
myotonic dystrophy type 1adult-onset Steinert myotonic dystrophylate-onset Steinert myotonic dystrophycongenital-onset Steinert myotonic dystrophy
HGNC:2933UniProt:Q09013
TUBB3Tubulin beta-3 chainDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Tubulin is the major constituent of microtubules, protein filaments consisting of alpha- and beta-tubulin heterodimers (PubMed:34996871, PubMed:38305685, PubMed:38609661). Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms (PubMed:34996871, PubMed:38305685, PubMed:38609661). Below the cap, alpha-beta tubulin heterodimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin (PubMed:34996871, PubMed:38609661). TUBB3 plays a cr

LOCALIZAÇÃO

Cytoplasm, cytoskeletonCell projection, growth coneCell projection, lamellipodiumCell projection, filopodium

VIAS BIOLÓGICAS (10)
HCMV Early EventsPKR-mediated signalingGap junction assemblyAggrephagyAssembly and cell surface presentation of NMDA receptors
MECANISMO DE DOENÇA

Fibrosis of extraocular muscles, congenital, 3A

A congenital ocular motility disorder marked by restrictive ophthalmoplegia affecting extraocular muscles innervated by the oculomotor and/or trochlear nerves. It is clinically characterized by anchoring of the eyes in downward gaze, ptosis, and backward tilt of the head. Congenital fibrosis of extraocular muscles type 3 presents as a non-progressive, autosomal dominant disorder with variable expression. Patients may be bilaterally or unilaterally affected, and their oculo-motility defects range from complete ophthalmoplegia (with the eyes fixed in a hypo- and exotropic position), to mild asymptomatic restrictions of ocular movement. Ptosis, refractive error, amblyopia, and compensatory head positions are associated with the more severe forms of the disorder. In some cases, the ocular phenotype is accompanied by additional features including developmental delay, corpus callosum agenesis, basal ganglia dysmorphism, facial weakness, polyneuropathy.

EXPRESSÃO TECIDUAL(Ubíquo)
Hipotálamo
143.8 TPM
Brain Frontal Cortex BA9
123.1 TPM
Córtex cerebral
102.0 TPM
Cérebro - Hemisfério cerebelar
101.2 TPM
Cerebelo
101.0 TPM
OUTRAS DOENÇAS (4)
fibrosis of extraocular muscles, congenital, 3A, with or without extraocular involvementcomplex cortical dysplasia with other brain malformations 1congenital fibrosis of extraocular musclestubulinopathy-associated dysgyria
HGNC:20772UniProt:Q13509
B3GALNT2UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Beta-1,3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAc-beta-1-3GlcNAc, on N- and O-glycans. Has no galactose nor galactosaminyl transferase activity toward any acceptor substrate. Involved in alpha-dystroglycan (DAG1) glycosylation: acts coordinately with GTDC2/POMGnT2 to synthesize a GalNAc-beta3-GlcNAc-beta-terminus at the 4-position of protein O-mannose in the biosynthesis of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3

LOCALIZAÇÃO

Golgi apparatus membraneEndoplasmic reticulum

VIAS BIOLÓGICAS (1)
DAG1 core M3 glycosylations
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A11

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

OUTRAS DOENÇAS (4)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type a, 11muscular dystrophy-dystroglycanopathy, type Aautosomal recessive non-syndromic intellectual disabilitymuscle-eye-brain disease
HGNC:28596UniProt:Q8NCR0
EMDEmerinDisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Stabilizes and promotes the formation of a nuclear actin cortical network. Stimulates actin polymerization in vitro by binding and stabilizing the pointed end of growing filaments. Inhibits beta-catenin activity by preventing its accumulation in the nucleus. Acts by influencing the nuclear accumulation of beta-catenin through a CRM1-dependent export pathway. Links centrosomes to the nuclear envelope via a microtubule association. Required for proper localization of non-farnesylated prelamin-A/C.

LOCALIZAÇÃO

Nucleus inner membraneNucleus outer membrane

VIAS BIOLÓGICAS (3)
Initiation of Nuclear Envelope (NE) ReformationNuclear Envelope BreakdownDepolymerization of the Nuclear Lamina
MECANISMO DE DOENÇA

Emery-Dreifuss muscular dystrophy 1, X-linked

A form of Emery-Dreifuss muscular dystrophy, a degenerative myopathy characterized by weakness and atrophy of muscle without involvement of the nervous system, early contractures of the elbows, Achilles tendons and spine, and cardiomyopathy associated with cardiac conduction defects.

EXPRESSÃO TECIDUAL(Ubíquo)
Ovário
236.6 TPM
Artéria tibial
203.8 TPM
Útero
199.2 TPM
Fallopian Tube
185.4 TPM
Cervix Endocervix
177.1 TPM
OUTRAS DOENÇAS (2)
Emery-Dreifuss muscular dystrophy 1, X-linkedX-linked Emery-Dreifuss muscular dystrophy
HGNC:3331UniProt:P50402
DOK7Protein Dok-7Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Probable muscle-intrinsic activator of MUSK that plays an essential role in neuromuscular synaptogenesis. Acts in aneural activation of MUSK and subsequent acetylcholine receptor (AchR) clustering in myotubes. Induces autophosphorylation of MUSK

LOCALIZAÇÃO

Cell membraneSynapse

MECANISMO DE DOENÇA

Myasthenic syndrome, congenital, 10

A form of congenital myasthenic syndrome, a group of disorders characterized by failure of neuromuscular transmission, including pre-synaptic, synaptic, and post-synaptic disorders that are not of autoimmune origin. Clinical features are easy fatigability and muscle weakness affecting the axial and limb muscles (with hypotonia in early-onset forms), the ocular muscles (leading to ptosis and ophthalmoplegia), and the facial and bulbar musculature (affecting sucking and swallowing, and leading to dysphonia). The symptoms fluctuate and worsen with physical effort. CMS10 is an autosomal recessive, post-synaptic form characterized by a typical 'limb girdle' pattern of muscle weakness with small, simplified neuromuscular junctions but normal acetylcholine receptor and acetylcholinesterase function.

EXPRESSÃO TECIDUAL(Ubíquo)
Pituitária
28.4 TPM
Coração - Átrio
27.8 TPM
Cerebelo
21.0 TPM
Músculo esquelético
19.7 TPM
Cérebro - Hemisfério cerebelar
19.5 TPM
OUTRAS DOENÇAS (4)
congenital myasthenic syndrome 10fetal akinesia deformation sequence 3postsynaptic congenital myasthenic syndromefetal akinesia deformation sequence 1
HGNC:26594UniProt:Q18PE1
DYSFDysferlinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Key calcium ion sensor involved in the Ca(2+)-triggered synaptic vesicle-plasma membrane fusion. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress (By similarity)

LOCALIZAÇÃO

Cell membrane, sarcolemmaCytoplasmic vesicle membraneCell membraneLate endosome membrane

VIAS BIOLÓGICAS (1)
Smooth Muscle Contraction
MECANISMO DE DOENÇA

Muscular dystrophy, limb-girdle, autosomal recessive 2

An autosomal recessive degenerative myopathy characterized by weakness and atrophy starting in the proximal pelvifemoral muscles, with onset in the late teens or later, massive elevation of serum creatine kinase levels and slow progression. Scapular muscle involvement is minor and not present at onset. Upper limb girdle involvement follows some years after the onset in lower limbs.

EXPRESSÃO TECIDUAL(Ubíquo)
Sangue
164.1 TPM
Baço
67.3 TPM
Músculo esquelético
44.4 TPM
Pulmão
30.5 TPM
Cólon sigmoide
23.4 TPM
OUTRAS DOENÇAS (6)
autosomal recessive limb-girdle muscular dystrophy type 2Bdistal myopathy with anterior tibial onsetMiyoshi muscular dystrophy 1autosomal recessive limb-girdle muscular dystrophy
HGNC:3097UniProt:O75923
LDB3LIM domain-binding protein 3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May function as an adapter in striated muscle to couple protein kinase C-mediated signaling via its LIM domains to the cytoskeleton

LOCALIZAÇÃO

Cytoplasm, perinuclear regionCell projection, pseudopodiumCytoplasm, cytoskeletonCytoplasm, myofibril, sarcomere, Z line

MECANISMO DE DOENÇA

Cardiomyopathy, dilated, 1C, with or without left ventricular non-compaction

A disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death. Cardiomyopathy dilated type 1C is associated with left ventricular non-compaction in some patients. Left ventricular non-compaction is characterized by numerous prominent trabeculations and deep intertrabecular recesses in hypertrophied and hypokinetic segments of the left ventricle.

EXPRESSÃO TECIDUAL(Ubíquo)
Coração - Ventrículo esquerdo
372.3 TPM
Músculo esquelético
338.8 TPM
Coração - Átrio
299.7 TPM
Artéria tibial
89.9 TPM
Aorta
57.8 TPM
OUTRAS DOENÇAS (7)
myofibrillar myopathy 4dilated cardiomyopathy 1Cfamilial isolated arrhythmogenic ventricular dysplasia, left dominant formfamilial isolated arrhythmogenic ventricular dysplasia, biventricular form
HGNC:15710UniProt:O75112
FKTNRibitol-5-phosphate transferase FKTNDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the transfer of a ribitol-phosphate from CDP-ribitol to the distal N-acetylgalactosamine of the phosphorylated O-mannosyl trisaccharide (N-acetylgalactosamine-beta-3-N-acetylglucosamine-beta-4-(phosphate-6-)mannose), a carbohydrate structure present in alpha-dystroglycan (DAG1) (PubMed:26923585, PubMed:27194101, PubMed:29477842). This constitutes the first step in the formation of the ribitol 5-phosphate tandem repeat which links the phosphorylated O-mannosyl trisaccharide to the ligan

LOCALIZAÇÃO

Golgi apparatus membraneCytoplasmNucleus

VIAS BIOLÓGICAS (1)
Matriglycan biosynthesis on DAG1
MECANISMO DE DOENÇA

Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A4

An autosomal recessive disorder characterized by congenital muscular dystrophy associated with cobblestone lissencephaly and other brain anomalies, eye malformations, profound intellectual disability, and death usually in the first years of life. Included diseases are the more severe Walker-Warburg syndrome and the slightly less severe muscle-eye-brain disease.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
21.9 TPM
Nervo tibial
12.9 TPM
Ovário
12.1 TPM
Útero
10.6 TPM
Cérebro - Hemisfério cerebelar
10.4 TPM
OUTRAS DOENÇAS (8)
muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4autosomal recessive limb-girdle muscular dystrophy type 2Mmuscular dystrophy-dystroglycanopathy (congenital without intellectual disability), type B4dilated cardiomyopathy 1X
HGNC:3622UniProt:O75072
TCAPTelethoninDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Muscle assembly regulating factor. Mediates the antiparallel assembly of titin (TTN) molecules at the sarcomeric Z-disk

LOCALIZAÇÃO

Cytoplasm, myofibril, sarcomere

VIAS BIOLÓGICAS (1)
Striated Muscle Contraction
MECANISMO DE DOENÇA

Cardiomyopathy, familial hypertrophic, 25

A hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.

EXPRESSÃO TECIDUAL(Ubíquo)
Músculo esquelético
2504.5 TPM
Coração - Ventrículo esquerdo
1812.2 TPM
Coração - Átrio
1252.5 TPM
Cerebelo
14.4 TPM
Cérebro - Hemisfério cerebelar
12.1 TPM
OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type 2Ghypertrophic cardiomyopathy 25familial isolated dilated cardiomyopathy
HGNC:11610UniProt:O15273
POGLUT1Protein O-glucosyltransferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Dual specificity glycosyltransferase that catalyzes the transfer of glucose and xylose from UDP-glucose and UDP-xylose, respectively, to a serine residue found in the consensus sequence of C-X-S-X-P-C (PubMed:21081508, PubMed:21490058, PubMed:21949356, PubMed:27807076, PubMed:28775322). Specifically targets extracellular EGF repeats of protein such as CRB2, F7, F9 and NOTCH2 (PubMed:21081508, PubMed:21490058, PubMed:21949356, PubMed:27807076, PubMed:28775322). Acts as a positive regulator of Not

LOCALIZAÇÃO

Endoplasmic reticulum lumen

VIAS BIOLÓGICAS (1)
Pre-NOTCH Processing in the Endoplasmic Reticulum
MECANISMO DE DOENÇA

Dowling-Degos disease 4

A form of Dowling-Degos disease, a genodermatosis manifesting with postpubertal reticulate hyperpigmentation that is progressive and disfiguring, and small hyperkeratotic dark brown papules that affect mainly the flexures and great skin folds. Patients usually show no abnormalities of the hair or nails. DDD4 is characterized by prominent involvement of non-flexural skin areas.

EXPRESSÃO TECIDUAL(Ubíquo)
Útero
18.8 TPM
Linfócitos
18.3 TPM
Cervix Ectocervix
17.1 TPM
Cervix Endocervix
16.6 TPM
Baço
16.2 TPM
OUTRAS DOENÇAS (3)
autosomal recessive limb-girdle muscular dystrophy type 2R1Dowling-Degos disease 4Dowling-Degos disease
HGNC:22954UniProt:Q8NBL1
DPM2Dolichol phosphate-mannose biosynthesis regulatory proteinCandidate gene tested inTolerante
FUNÇÃO

Regulates the biosynthesis of dolichol phosphate-mannose (PubMed:10835346). Regulatory subunit of the dolichol-phosphate mannose (DPM) synthase complex; essential for the ER localization and stable expression of DPM1 (PubMed:10835346). Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis (PubMed:161628

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (5)
Synthesis of dolichyl-phosphate mannoseMaturation of DENV proteinsDefective DPM3 causes DPM3-CDGDefective DPM1 causes DPM1-CDGSynthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Congenital disorder of glycosylation 1U

A form of congenital disorder of glycosylation, a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions. Some CDG1U patients have dystrophic changes seen on muscle biopsy and reduced O-mannosyl glycans on alpha-dystroglycan.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
86.9 TPM
Fibroblastos
64.0 TPM
Próstata
61.1 TPM
Cervix Endocervix
59.8 TPM
Cervix Ectocervix
57.1 TPM
OUTRAS DOENÇAS (1)
congenital muscular dystrophy with intellectual disability and severe epilepsy
HGNC:3006UniProt:O94777

Medicamentos e terapias

ETEPLIRSENPhase 4

Mecanismo: Dystrophin pre-mRNA positive modulator

ATALURENPhase 4

Mecanismo: 80S Ribosome modulator

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

10,571 variantes patogênicas registradas no ClinVar.

🧬 DMD: NM_004006.3(DMD):c.10922-18G>A ()
🧬 DMD: NM_004006.3(DMD):c.5047A>T (p.Thr1683Ser) ()
🧬 DMD: NM_004006.3(DMD):c.8240C>T (p.Ala2747Val) ()
🧬 DMD: NM_004006.3(DMD):c.4448T>C (p.Met1483Thr) ()
🧬 DMD: NM_004006.3(DMD):c.3603+13_3603+14insG ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 83,709 variantes classificadas pelo ClinVar.

8371
37669
37669
Patogênica (10.0%)
VUS (45.0%)
Benigna (45.0%)
VARIANTES MAIS SIGNIFICATIVAS
SMCHD1: NM_015295.3(SMCHD1):c.1464-2A>G [Likely pathogenic]
POMGNT2: NM_032806.6(POMGNT2):c.740_741del (p.Phe247fs) [Pathogenic]
DMD: NM_004006.3(DMD):c.5047A>T (p.Thr1683Ser) [Uncertain significance]
DMD: NM_004006.3(DMD):c.8240C>T (p.Ala2747Val) [Uncertain significance]
DMD: NM_004006.3(DMD):c.4448T>C (p.Met1483Thr) [Uncertain significance]

Vias biológicas (Reactome)

130 vias biológicas associadas aos genes desta condição.

Non-integrin membrane-ECM interactions Striated Muscle Contraction Formation of the dystrophin-glycoprotein complex (DGC) Collagen degradation Collagen biosynthesis and modifying enzymes Assembly of collagen fibrils and other multimeric structures Collagen chain trimerization Synthesis of dolichyl-phosphate mannose Defective DPM1 causes DPM1-CDG Defective DPM3 causes DPM3-CDG Defective DPM2 causes DPM2-CDG Maturation of DENV proteins Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 DAG1 core M2 glycosylations DAG1 core M1 glycosylations Matriglycan biosynthesis on DAG1 Caspase-mediated cleavage of cytoskeletal proteins Type I hemidesmosome assembly ABC transporters in lipid homeostasis RHOA GTPase cycle RHOC GTPase cycle Class I peroxisomal membrane protein import Synthesis of PC Synthesis of PE Defective LARGE causes MDDGA6 and MDDGB6 Molecules associated with elastic fibres TGF-beta receptor signaling activates SMADs NOTCH2 Activation and Transmission of Signal to the Nucleus Expression of NOTCH2NL genes COPI-dependent Golgi-to-ER retrograde traffic Kinesins FGFR1b ligand binding and activation FGFR1c ligand binding and activation TGFBR3 regulates TGF-beta signaling TGFBR3 regulates FGF2 signaling RAB GEFs exchange GTP for GDP on RABs Degradation of the extracellular matrix Signaling by PDGF Integrin cell surface interactions ECM proteoglycans NCAM1 interactions FGFR2 alternative splicing NRIF signals cell death from the nucleus p75NTR recruits signalling complexes NF-kB is activated and signals survival PINK1-PRKN Mediated Mitophagy Neddylation Interleukin-1 signaling Pexophagy Signaling by ALK fusions and activated point mutants KEAP1-NFE2L2 pathway Nuclear events mediated by NFE2L2 Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 DAG1 core M3 glycosylations Regulation of CDH1 posttranslational processing and trafficking to plasma membrane HSF1-dependent transactivation Synthesis of PIPs at the plasma membrane Smooth Muscle Contraction Laminin interactions MET activates PTK2 signaling EGR2 and SOX10-mediated initiation of Schwann cell myelination Attachment of bacteria to epithelial cells Developmental Lineage of Pancreatic Ductal Cells Complement cascade SARS-CoV-2 activates/modulates innate and adaptive immune responses Regulation of expression of SLITs and ROBOs Retinoid metabolism and transport mRNA Splicing - Major Pathway Processing of Capped Intron-Containing Pre-mRNA Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation mRNA Polyadenylation Dengue Virus-Host Interactions Synthesis of GDP-mannose Meiotic synapsis Nuclear Envelope Breakdown Initiation of Nuclear Envelope (NE) Reformation Breakdown of the nuclear lamina XBP1(S) activates chaperone genes Depolymerization of the Nuclear Lamina Signaling by BRAF and RAF1 fusions Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models PPARA activates gene expression Activation of gene expression by SREBF (SREBP) Lanosterol biosynthesis Stimuli-sensing channels Induction of Cell-Cell Fusion PRC2 methylates histones and DNA NoRC negatively regulates rRNA expression SUMOylation of DNA methylation proteins DNA methylation Defective pyroptosis Keratan sulfate biosynthesis Ion homeostasis Translocation of SLC2A4 (GLUT4) to the plasma membrane Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane Gap junction assembly MHC class II antigen presentation Separation of Sister Chromatids Resolution of Sister Chromatid Cohesion HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Recruitment of NuMA to mitotic centrosomes Prefoldin mediated transfer of substrate to CCT/TriC Formation of tubulin folding intermediates by CCT/TriC Post-chaperonin tubulin folding pathway Recycling pathway of L1 Hedgehog 'off' state Cargo trafficking to the periciliary membrane Intraflagellar transport RHO GTPases activate IQGAPs RHO GTPases Activate Formins COPI-mediated anterograde transport COPI-independent Golgi-to-ER retrograde traffic Mitotic Prometaphase The role of GTSE1 in G2/M progression after G2 checkpoint Carboxyterminal post-translational modifications of tubulin HCMV Early Events Assembly and cell surface presentation of NMDA receptors Activation of AMPK downstream of NMDARs Aggrephagy EML4 and NUDC in mitotic spindle formation Sealing of the nuclear envelope (NE) by ESCRT-III RAC1 GTPase cycle RAC2 GTPase cycle RHOD GTPase cycle RHOG GTPase cycle RAC3 GTPase cycle Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Pre-NOTCH Processing in the Endoplasmic Reticulum Synthesis of glycosylphosphatidylinositol (GPI)

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado2
2Fase 24
1Fase 13
·Pré-clínico13
Medicamentos catalogadosEnsaios clínicos· 2 medicamentos · 20 ensaios
✓ Aprovados — podem ser usados hoje
ETEPLIRSENATALUREN
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Distrofia muscular

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

18 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

856 ensaios clínicos encontrados, 29 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
11.548 papers (10 anos)

Mostrando amostra de 200 publicações de um total de 11.548

#1

Wearable technologies in clinical trials for drug development: trends and emerging opportunities.

Nature reviews. Drug discovery2026 Mar 23

As tecnologias vestíveis (wearables) estão transformando os ensaios clínicos, permitindo coletar dados contínuos e em tempo real sobre a saúde de pacientes em seu ambiente natural. Isso oferece a médicos e pacientes uma compreensão mais precisa de como os medicamentos atuam e podem ser otimizados, além de reduzir a necessidade de visitas frequentes ao hospital. Na Distrofia Muscular de Duchenne, por exemplo, uma medida específica (SV95C) obtida via wearables já tem qualificação regulatória, demonstrando o potencial dessas ferramentas no avanço do desenvolvimento de tratamentos.

🇧🇷 traduzido
#2

Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score.

Journal of neurology2026 Mar 23

Este estudo avaliou a pontuação MOG-AR, desenvolvida para prever recaídas na doença associada a anticorpos anti-MOG (MOGAD) e guiar decisões de tratamento. Contudo, numa coorte de pacientes do Reino Unido, a pontuação teve um desempenho abaixo do ideal, mostrando-se limitada na previsão precisa de recaídas em três anos e superestimando as probabilidades. Isso destaca a necessidade de ferramentas preditivas mais eficazes para ajudar médicos e pacientes a planejar as estratégias de tratamento desde o início da MOGAD.

🇧🇷 traduzido
#3

Investigation of Walking Ability in 161 Patients With Duchenne Muscular Dystrophy.

Clinical pediatrics2026 Mar 23

Este estudo com 161 pacientes com Distrofia Muscular de Duchenne (DMD) revelou que a terapia hormonal precoce, a frequência escolar e um bom suporte social são fatores cruciais para preservar a capacidade de caminhar. Níveis mais baixos de vitamina D também foram associados à perda de ambulação. Para otimizar e prolongar a capacidade de andar, é fortemente recomendado para pacientes e médicos combinar terapia hormonal com reabilitação consistente e engajamento escolar.

🇧🇷 traduzido
#4

CTLA4-Ig reduces proliferation and inflammatory gene expression in muscle fibroblasts, corresponding to less fibrosis and inflammation in mdx muscular dystrophy.

American journal of physiology. Cell physiology2026 Mar 19

Um estudo pré-clínico em camundongos com distrofia muscular (modelo mdx) demonstrou que o tratamento com CTLA4-Ig reduziu significativamente o dano muscular, a inflamação e a fibrose, aspectos cruciais da progressão da doença. Curiosamente, essa melhora ocorreu por uma ação direta do CTLA4-Ig nos fibroblastos musculares – células que contribuem para a fibrose – diminuindo sua proliferação e a expressão de genes pró-inflamatórios, e não primariamente pelo bloqueio da ativação de células T. Isso sugere uma nova e promissora via terapêutica para pacientes, focada na modulação direta da fibrose.

🇧🇷 traduzido
#5

Cracking the Code: Genotype-Phenotype Correlation Models in Sarcoglycanopathies.

Annals of clinical and translational neurology2026 Mar 19

Este estudo estabeleceu correlações genótipo-fenótipo robustas para as sarcoglicanopatias, um grupo de distrofias musculares graves com apresentações variáveis, cuja progressão era anteriormente difícil de prever. Ao analisar uma grande coorte e identificar variantes genéticas que afetam criticamente o transporte de proteínas, os pesquisadores desenvolveram um modelo preditivo de alta precisão, agora disponível como uma ferramenta de acesso aberto. Para pacientes e médicos, isso significa uma melhoria significativa no prognóstico, na gestão do tratamento e na seleção de indivíduos para ensaios clínicos.

🇧🇷 traduzido

Publicações recentes

Ver todas no PubMed

📚 EuropePMC17.095 artigos no totalmostrando 198

2026

Wearable technologies in clinical trials for drug development: trends and emerging opportunities.

Nature reviews. Drug discovery
2026

Correlative multimodal imaging for microscale spatial mapping of collagen-gene activity interactions in human tissues.

Npj imaging
2026

Complete genetic and epigenetic architecture of D4Z4 macrosatellites in FSHD, BAMS, and reference cohorts with D4Z4End2End.

Genome research
2026

Progress on cell therapy for skeletal muscle disorders.

Advanced drug delivery reviews
2026

Unmet Needs in the Care of Patients with Duchenne Muscular Dystrophy in Brazil.

Arquivos de neuro-psiquiatria
2026

Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score.

Journal of neurology
2026

Optical Genome Mapping and Long-Read Sequencing Identifies a Novel Dystrophin Gene Inversion in a Patient With Duchenne Muscular Dystrophy.

American journal of medical genetics. Part A
2026

DAB2 in LGMD R2: a molecular link between disease progression and lipid dysregulation.

JCI insight
2026

Global MyoG research 2004-2024: a bibliometric analysis of trends and translational implications.

Experimental biology and medicine (Maywood, N.J.)
2026

Investigation of Walking Ability in 161 Patients With Duchenne Muscular Dystrophy.

Clinical pediatrics
2026

Thorough QT Study on the Effect of Therapeutic and Supratherapeutic Dosing of Givinostat in Healthy Volunteers.

Clinical pharmacology in drug development
2026

Evaluation of the methodology of independent Community Advisory Boards in health products research and development: a mixed-methods cross-sectional survey study.

Research involvement and engagement
2026

Late-onset facioscapulohumeral muscular dystrophy defines a distinct clinical subgroup.

Neuromuscular disorders : NMD
2026

Motor Function and Growth Outcomes With Early Corticosteroid Initiation in Duchenne Muscular Dystrophy: An Adjusted Cross-Trial Comparison.

Muscle & nerve
2026

Viscoelastic properties of dystrophin-deficient mouse skeletal muscles are resilient to isometric fatiguing exercise.

Physiological reports
2026

Euglycemic ketoacidosis in a nondiabetic patient with Duchenne muscular dystrophy on dapagliflozin: comment.

Internal and emergency medicine
2026

Laminin-α2 is required for the maintenance of the myotendinous junction in vivo.

Matrix biology : journal of the International Society for Matrix Biology
2026

CTLA4-Ig reduces proliferation and inflammatory gene expression in muscle fibroblasts, corresponding to less fibrosis and inflammation in mdx muscular dystrophy.

American journal of physiology. Cell physiology
2026

Clinico-genetic heterogeneity in Pakistani families affected with muscular dystrophies.

Molecular biology reports
2026

Sirolimus for the treatment of steroid-refractory hepatotoxicity following AAV gene therapy in patients with Duchenne muscular dystrophy.

Journal of neuromuscular diseases
2026

Cracking the Code: Genotype-Phenotype Correlation Models in Sarcoglycanopathies.

Annals of clinical and translational neurology
2026

Co-occurring DMD, GJA1, and novel FYCO1 variants in a proband from a consanguineous oculodentodigital dysplasia family: a rare multi-locus case report.

Frontiers in genetics
2026

Mapping neurogenic dysphagia diagnostics in Germany: accessibility, implementation practices, and barriers to swallowing endoscopy.

Neurological research and practice
2026

Lysosomal phosphoinositide turnover acts upstream of RagGTPase-mTORC1 and controls muscle growth.

Nature metabolism
2026

Impact of C4BPA on Muscle progenitor cell differentiation: insights for Duchenne muscular dystrophy treatment.

Cell death & disease
2026

Myofibre Density Reveals a Critical Threshold Around Age 6 in Steroid-Naïve Duchenne Muscular Dystrophy: A Retrospective Observational Study.

Neuropathology and applied neurobiology
2026

Molecular and Cellular Mechanisms of Sarcopenia: Integrating Fiber-Type Remodeling, Contractile Protein Dynamics, and Systemic Regulatory Pathways.

Cell biochemistry and function
2026

Wernicke Encephalopathy Complicating a Distinctive POLG Phenotype With MNGIE-Like Features.

European journal of neurology
2026

CRISPR Gene Editing for Nucleotide Repeat Expansion Disorders: A Systematic Review of Preclinical and Clinical Evidence.

Genetic testing and molecular biomarkers
2026

X-linked Emery-Dreifuss muscular dystrophy caused by a novel FHL1 mutation: A case report.

The Journal of international medical research
2026

Pearls & Oy-sters: Use of Short-Acting B-Agonist in DOK7-Related Congenital Myasthenic Syndrome Treatment.

Neurology
2026

Approaching Serious Illness Conversations in Amyotrophic Lateral Sclerosis Using Telehealth: A Practical Guide.

Neurology. Clinical practice
2026

Rethinking Corticosteroid Therapy in Pediatric Neurology.

Journal of inflammation research
2026

Economic burden of Duchenne muscular dystrophy from a societal perspective in Mumbai, India.

Journal of postgraduate medicine
2026

Phase separation of DUX family proteins drives totipotent-like state via 3D genome reorganization and retrotransposon activation.

Protein & cell
2026

Hypertransaminasemia as an initial manifestation of muscular dystrophy in childhood.

Medicina clinica
2026

Exosome-Mediated Benefits of Cell Therapy in Mouse and Human Models of Duchenne Muscular Dystrophy.

Stem cell reports
2026

Burden of illness of Duchenne muscular dystrophy in Belgium: A retrospective, descriptive, cross-sectional study.

Journal of neuromuscular diseases
2026

Adult SMA REACH: A UK clinical network and real-world data collection study for adults living with spinal muscular atrophy.

Journal of neuromuscular diseases
2026

Skipping the Biopsy: Real-World Experience of Whole-Exome Sequencing as First-Tier Testing in Pediatric Muscular Disorders.

International journal of molecular sciences
2026

Best reference genes for unbiased normalized transcript expression in normal and dystrophic human cell models of myogenesis.

PloS one
2026

A Novel Dysferlin-Binding Kinase CK2α Promotes Plasma Membrane Repair in Dysferlinopathy.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

Mutation of leucine 170 alters the subcellular distribution, neurite outgrowth and three-dimensional structure of dystrophins Dp71 and Dp40.

Molecular biology reports
2026

Hearing, Voice and Speech Disorders in 10-Year-Old-Boy with Facio-Scapulo-Humeral Dystrophy (FSHD) - Case Study.

The application of clinical genetics
2026

Evaluation of Dysphagia in Myositis and Muscular Dystrophy Using Real-Time MRI and Quantitative Muscle Ultrasound.

Journal of cachexia, sarcopenia and muscle
2026

Delpacibart etedesiran improves the molecular pathology of myotonic dystrophy type 1 in the phase 1/2 MARINA study.

Molecular therapy : the journal of the American Society of Gene Therapy
2026

PTBP1 inhibition reprograms myogenesis to rescue impaired muscle regeneration in mdx mice through correcting E2A splicing.

Nature communications
2026

Dystrophin-Deficient Cardiomyopathy Due to a Novel Hemizygous DMD Indel Variant.

JACC. Case reports
2026

A Retrospective Analysis of Human Angiotensin II Receptor Blockers (ARB) Pharmacokinetics, Dosages and Cmax Values for the Experimental Modelling of Pleiotropic and Supratherapeutic Activities.

Basic & clinical pharmacology & toxicology
2026

SORT LNPs encapsulating Cas9 mRNA achieve efficient editing in skeletal muscle in a dystrophic mouse model.

Molecular therapy : the journal of the American Society of Gene Therapy
2026

Conjugated Antisense Oligonucleotides for Skipping of Duchenne Muscular Dystrophy Exon 53: A Cautionary Study.

Nucleic acid therapeutics
2026

Early postsynaptic instability and acetylcholine receptor compartmentalization precede neuromuscular synapse dismantling.

Communications biology
2026

An Assessment of Paediatricians' Knowledge and Perspectives of Duchenne Muscular Dystrophy in Oman.

Sultan Qaboos University medical journal
2026

Liver health in myotubular and centronuclear myopathies: a patient-driven data collection study to better understand liver health and improve standards of care.

Neuromuscular disorders : NMD
2026

Gait analysis reveals new outcome measures for monitoring disease progression in individuals with late-onset Pompe disease.

Journal of neuroengineering and rehabilitation
2026

Pharyngeal electrical stimulation for postextubation dysphagia after stroke: a randomized trial on hospitalization costs from a health insurance perspective.

Scientific reports
2026

Duchenne Muscular Dystrophy Presenting as Acute Flaccid Paralysis: Authors' Reply.

Indian journal of pediatrics
2026

LAMA2 Triple Variant in a Mexican Child with Congenital Muscular Dystrophy.

Annals of Indian Academy of Neurology
2026

Genetic insights into syndromic anophthalmia/microphthalmia: novel molecular findings in a prenatal context.

Ophthalmic genetics
2026

Identifying Neurodevelopmental Domain Subgroups in Autism and ADHD.

Journal of autism and developmental disorders
2026

Bioengineered AAV9 and Optimised Microdystrophin Vectors Augment Phenotypic Rescue in a Murine Model of Duchenne Muscular Dystrophy.

Journal of cellular and molecular medicine
2026

Evaluation and management of DMD gene copy number variations detected by prenatal SNP-array testing.

BMC medical genomics
2026

Key Principles and Disease-Specific Considerations to Guide Management of Bone Health and Osteoporosis Among Individuals With Neuromuscular Disorders: The Path Forward.

Muscle & nerve
2026

Framing childhood-onset facioscapulohumeral dystrophy: from first symptoms to future trials.

Neuromuscular disorders : NMD
2026

Real-world walking speed as a digital biomarker and outcome measure for clinical trials-a systematic review, regulatory status and future directions.

Frontiers in digital health
2026

Cosegregation of congenital dysferlinopathy phenotype and marinesco-sjögren syndrome: a case report with literature review.

BMC pediatrics
2026

Overview of facioscapulohumeral dystrophy clinical features and diagnostic pathway.

Neuromuscular disorders : NMD
2026

If Becker Muscular Dystrophy Initially Manifests with Heart Disease and Rhabdomyolysis, Neurological Work-up Is Imperative.

Internal medicine (Tokyo, Japan)
2026

Status of Clinical Care of Duchenne Muscular Dystrophy: Global Perspective and Situation in India.

Indian journal of pediatrics
2026

A muscular dystrophy associated with bi-allelic LEMD2 variants: Expanding the genotype of nuclear envelopathies.

Brain pathology (Zurich, Switzerland)
2026

Longitudinal ankle range of motion and functional decline in Duchenne muscular dystrophy.

Neuromuscular disorders : NMD
2026

Results of a phase II open-label, multiple-dose study of vamorolone (VBP15-006) in 7- to < 18-year-old boys with duchenne muscular dystrophy.

Journal of neurology
2025

Fat embolism syndrome in Duchenne muscular dystrophy: an underdiagnosed complication.

Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology
2026

Pyroxd1 is essential for murine viability with the homozygous N155S recurrent variant linked to myopathy, muscle hypotrophy and osteopenia.

Acta neuropathologica communications
2026

Prospective Validation of the New PLS Diagnostic Criteria From PLS Natural History Study: EMG and Neurofilament Analyses.

Muscle &amp; nerve
2026

Decoding genetic complexity in glycogen storage diseases: three novel variants in SLC37A4, GAA, and PHKG2 identified in an Iranian cohort.

Neuromuscular disorders : NMD
2026

Cargo Recognition of Nesprin-2 by the Dynein Adapter Bicaudal D2 for a Nuclear Positioning Pathway That Is Important for Brain Development.

Biochemistry
2026

The Amyotrophic Lateral Sclerosis House Call Program: A Single-Center Experience in the United States.

Neurology research international
2026

Miglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.

Therapeutic advances in rare disease
2025

Randomised trial of Aureobasidium pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation.

BMJ nutrition, prevention &amp; health
2026

What Is in the Myopathy Literature?

Journal of clinical neuromuscular disease
2026

Expanding the phenotypic spectrum of LAMA2-related disorders: Axonal neuropathy in the absence of muscular dystrophy.

Journal of human genetics
2026

Personalized antioxidant supplementation improves muscle strength, physical activity, and quality of life in patients with FSHD1: A real-world longitudinal study.

Free radical biology &amp; medicine
2026

Respiratory function in Becker muscular dystrophy: a comprehensive longitudinal study.

Journal of neurology, neurosurgery, and psychiatry
2026

SMCHD1 loss re-wires MYOD1 enhancer nexuses and chromatin accessibility landscapes in muscle cells.

bioRxiv : the preprint server for biology
2026

Molecular Insights and Orthopedic Management in Muscular Dystrophies: A Comprehensive Review.

International journal of molecular sciences
2026

Potential Involvement of Ferroptosis in Duchenne Muscular Dystrophy-Associated Cardiomyopathy.

Biomedicines
2026

Effects of Bisphosphonates on Bone Micro-Architecture of Children With Duchenne Muscular Dystrophy: A Prospective Comparative Study.

Journal of cachexia, sarcopenia and muscle
2026

A comprehensive framework for the interpretation of TTN missense variants.

Genome medicine
2026

Pan-immune-inflammation value as a predictor of loss of ambulation in duchenne muscular dystrophy: a retrospective cohort study.

BMC pediatrics
2026

Management of Duchenne Muscular Dystrophy in Clinical Practice: A Survey-Based Study in Spain.

Neurology and therapy
2026

Senolytics and exercise: Dual modalities for rejuvenating muscle.

The Journal of physiology
2026

Analysis of adverse event reporting with casimersen: a pharmacovigilance study based on the United States food and drug administration adverse event reporting system database.

International journal of clinical pharmacy
2026

Inflammation at the core: rethinking pathology in limb-girdle muscular dystrophy R3.

Brain : a journal of neurology
2026

Elevated Risk of Endometrial Cancer and Precursor Lesions in Patients With Myotonic Dystrophy: A Retrospective Study at a Single Institution in Japan.

The journal of obstetrics and gynaecology research
2026

Exploring Patient Perspectives on an Immersive Virtual Reality Experience for Neuromuscular Diseases.

Games for health journal
2026

Implementing a Tiered Genetic Testing Strategy for Muscular Dystrophies in Morocco: From Targeted Assays to Exome Sequencing.

Molecular genetics &amp; genomic medicine
2026

Functional and structural pathologies in skeletal muscle of a rat model of Duchenne muscular dystrophy.

Skeletal muscle
2026

RNA cargo profiling of muscle extracellular vesicles identifies candidate biomarkers of disease activity and muscle degeneration in FSHD.

Journal of translational medicine
2026

Machine learning for site risk prediction in clinical trials: development, external validation, and operational application in site qualification.

International journal of medical informatics
2026

Duchenne Muscular Dystrophy Presenting as Acute Flaccid Paralysis: Correspondence.

Indian journal of pediatrics
2026

Assessing the multidimensional burden of facioscapulohumeral muscular dystrophy through patient-reported outcomes and experience.

Journal of patient-reported outcomes
2026

CD146 + interstitial cells contribute to the dystrophic skeletal muscle phenotype in vitro.

Scientific reports
2026

Population-Based Investigation of DMD Genotype and Neurodevelopmental Concerns in Duchenne Muscular Dystrophy.

Neuropediatrics
2026

Becker muscular dystrophy in a pediatric patient: A case report.

The Nurse practitioner
2026

Swallowing and Communication in Cockayne Syndrome: Clinical Characteristics and Management.

American journal of medical genetics. Part A
2026

Evaluation of Readthrough Efficiency of Negamycin Derivatives against Nonsense Mutations in Muscular Dystrophy Genes.

Biological &amp; pharmaceutical bulletin
2026

Disruption of BDNF signalling in neuropathologies.

Biochemical Society transactions
2026

The Paradox of Life Extension with Traditional Cost-Effectiveness Analysis: A Case Study with Duchenne Muscular Dystrophy.

Journal of health economics and outcomes research
2026

Dual AAV amelioration of Lama2-null muscular dystrophy and neuropathy.

bioRxiv : the preprint server for biology
2026

Statins in Genetic Myopathies: A Retrospective Analysis of Safety and Tolerability.

Neurology. Clinical practice
2026

CRPPA exon 6-9 deletion as a founder mutation in Chinese patients with dystroglycanopathy.

Pediatric investigation
2026

Senescent-Like Myofibers Contribute to Anti-Regenerative Cytokine Signaling in Duchenne Muscular Dystrophy.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
2026

Electrical Impedance Myography Detects Disease Progression over 12 to 24 Months in Facioscapulohumeral Muscular Dystrophy.

Annals of neurology
2026

Current evidence and knowledge gaps in family planning and pregnancy in myasthenia gravis, NMOSD, and MOGAD.

The Lancet. Neurology
2026

Safety and efficacy of fordadistrogene movaparvovec in ambulatory participants with Duchenne muscular dystrophy (CIFFREO): a phase 3, double-blind, randomised, placebo-controlled study.

The Lancet. Neurology
2026

Pathologic Variability Associated With Phenotypic Differences in Siblings With ACTA1 Myopathy.

Muscle &amp; nerve
2026

Clinical and Genetic Analysis of Limb-Girdle Muscular Dystrophy Type 2F with A Novel SGCD Mutation: A Case Report.

Cell journal
2026

Cardiac Performance Evaluation in Patients with Muscular Dystrophy.

Pediatric cardiology
2026

Dilated Cardiomyopathy and Later Onset Limb-Girdle Muscular Dystrophy Associated With Fukutin and LaminA/C Mutations.

JACC. Case reports
2026

Wernicke Encephalopathy Associated with Malabsorption in Degos Disease.

Journal of investigative medicine high impact case reports
2026

Anaesthetic considerations for a patient with Emery-Dreifuss muscular dystrophy undergoing cardiac resynchronisation therapy with pacemaker implantation.

Anaesthesia reports
2026

Early Cardiac Manifestations as the Initial Presentation of Duchenne Muscular Dystrophy in Infancy.

Cureus
2026

Trunk control status in children with neuromuscular disorders and typically developing children: Is there a measurable difference?

Journal of neuromuscular diseases
2026

Glomerular basement membrane structural integrity dictates trans-tissue deposition of laminin in the kidney.

Cell reports
2026

A simple and highly sensitive LC-MS/MS bioanalytical method for phosphorodiamidate morpholino oligonucleotides in plasma.

Bioanalysis
2026

Total intravenous anesthesia for cardiac transplantation in a teenager with Becker muscular dystrophy: A case report.

Saudi journal of anaesthesia
2026

Induction of senescence during postpartum mammary gland involution supports tissue remodeling and promotes postpartum tumorigenesis.

Nature aging
2026

The Impact of Trunk Control and Balance on Functional Skills in Ambulatory Children With Duchenne Muscular Dystrophy.

Journal of paediatrics and child health
2026

Test the grandfather! Incidental in-frame DMD deletions in three asymptomatic families.

Journal of medical genetics
2026

SNUPN variants cause spinocerebellar atrophy by disrupting global splicing in cerebellar Purkinje cells.

Brain : a journal of neurology
2026

Assessing the Relationship of Quality of Life With Functional Status in a Large Cohort of Adult Patients With Neuromuscular Disorders.

Neurology. Clinical practice
2026

GGC repeat expansions within new open reading frames are translated into toxic polyglycine proteins in oculopharyngodistal myopathy.

Nature genetics
2025

Exploratory analysis of smartphone-based step counts as a digital biomarker for survival in ALS patients.

Frontiers in digital health
2026

Molecular mechanisms of skeletal muscle fibrosis and potential targeted therapeutic strategies.

Frontiers in immunology
2026

Safety and Efficacy of Tamoxifen in Patients with Duchenne muscular dystrophy: open Label Extension of TAMDMD Trial.

Neuromuscular disorders : NMD
2026

Motor Function Changes in Duchenne Muscular Dystrophy: A Case Series Using Conventional and Spinal Muscular Atrophy-Based Assessments During Viltolarsen Treatment.

Pediatric neurology
2026

Clinical diagnosis and genetic analysis of a rare case of Duchenne muscular dystrophy and spinal muscular atrophy.

Molecular cytogenetics
2026

MLDP-AS: an optimized next-generation sequencing assay for enhanced detection of technically challenging variants in expanded carrier screening.

Journal of translational medicine
2026

Oligomer-dependent and oligomer-independent pathogenesis of muscular dystrophy-associated mutations within the penta-EF-hand domain of calpain-3.

The Journal of biological chemistry
2026

Generation of induced pluripotent stem cell lines from patients with Emery-Dreifuss muscular dystrophy.

Stem cell research
2026

A Narrative Review of Necroptosis in Neuromuscular Junction Disorders: Pathogenesis and Therapeutic Strategies.

Archives of medical research
2026

A roadmap for a patient-centred approach to Pompe disease management.

Journal of neurology
2026

Uncommon Associations in Duchenne Muscular Dystrophy: Coexistence of Patent Foramen Ovale and Ocular Anomalies.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
2026

Attenuated lamin A-prohibitin2 interaction leads to mitochondrial dysfunction in LMNA 289 A>G-mediated dilated cardiomyopathy.

The Journal of biological chemistry
2026

Protocol for in vivo analysis of muscle function in porcine models for muscular dystrophies.

STAR protocols
2026

A Translational Roadmap for Neurological Nonsense Mutation Disorders.

International journal of molecular sciences
2026

Macrophage Infiltration, Activation, and Therapeutic Implication in Skeletal Muscle Injury and Repair.

International journal of molecular sciences
2026

Learnings from Patient Mortality after Delandistrogene Moxeparvovec Administration: A Report of Two Cases and Expert Committee Considerations for Future Mitigation and Management.

Human gene therapy
2026

Patient reported outcome measures in spinal muscular atrophy and duchenne muscular dystrophy: review of instruments and their inclusion in clinical and regulatory processes.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
2026

Prognostic value of right ventricular-pulmonary artery coupling in patients with muscular dystrophies.

Scientific reports
2026

Missense variants in TUBA4A cause myo-tubulinopathies.

Brain : a journal of neurology
2026

Potential pitfalls in the differential diagnosis of myositis versus hereditary myopathies.

Clinical and experimental rheumatology
2026

Diagnostic Cut-off Values for Newly Developed Noninvasive Elastance-Based Indices in Duchenne Muscular Dystrophy-Associated Cardiomyopathy.

Pediatric cardiology
2026

Patient-Derived 3D Bioprinted Cardiac Organoid Constructs Reveal Key Pathological Features of Duchenne Muscular Dystrophy.

Advanced healthcare materials
2026

DYSF gene variant spectrum in Arab populations across eight countries: A systematic review.

Biomolecules &amp; biomedicine
2026

Recurrent Pneumonia in a Patient With Oculopharyngeal Muscular Dystrophy (OPMD) due to GCN Expansion in the PABPN1 Gene: A Diagnostic Challenge.

Open respiratory archives
2026

ALT/CK Ratio as an Early Marker of Liver Injury After Gene Therapy in Duchenne Muscular Dystrophy.

Pediatrics
2026

Correspondence on 'Cardiac MRI for early detection of subclinical cardiac dysfunction in dysferlinopathy' by Thomas et al.

Neuromuscular disorders : NMD
2026

The natural history of Becker muscular dystrophy: A systematic literature review.

Journal of neuromuscular diseases
2026

The Cerebellar Cognitive-Affective Syndrome Scale Reveals Consistent, Early, and Progressive Neuropsychological Deficits in Autosomal-Recessive Spastic Ataxia of Charlevoix-Saguenay: A Large International Cross-Sectional Study.

Movement disorders : official journal of the Movement Disorder Society
2026

Lost in translation: absence of KIAA1324/ELAPOR1 protein in pathological TDP-43-affected neurons in ALS/FTD.

Acta neuropathologica communications
2026

Structural basis of TACO1-mediated efficient mitochondrial translation.

Nature communications
2026

Lumbopelvic stabilization-based physiotherapy and rehabilitation and urotherapy for lower urinary tract dysfunction in Duchenne Muscular Dystrophy: a randomized controlled trial.

Jornal de pediatria
2026

Early Diagnosis of Duchenne Muscular Dystrophy Requires Newborn Screening for CK, and in the Event of Paresis, Relevant Investigations.

Journal of child neurology
2026

Acute Liver Failure With Transient Liver Steatosis Following Multiple Hits Postoperatively in a Patient With Limb-Girdle Muscular Dystrophy: A Case Report.

Clinical case reports
2026

Survival of Intravenous Edaravone-Treated Patients With ALS: Evidence From Administrative Claims Analyses.

Muscle &amp; nerve
2026

DUCKS4: a comprehensive workflow for Nanopore sequencing analysis of facioscapulohumeral muscular dystrophy (FSHD).

Human genomics
2026

Evaluation of protein expression and oxidative stress index in Duchenne muscular dystrophy.

Pediatric research
2026

Gene-based Therapies for Genetic Cardiomyopathies: Molecular Medicine for Heart Disease.

The Canadian journal of cardiology
2026

Kinematic features of dysphagia in inclusion body myositis.

Neuromuscular disorders : NMD
2026

Clinically important improvements in 6-minute walk distance and forced vital capacity in adults with late-onset Pompe disease switching from alglucosidase alfa to cipaglucosidase alfa plus miglustat in the PROPEL study.

Neuromuscular disorders : NMD
2026

A randomized, double-blind, placebo-controlled study of losmapimod in patients with facioscapulohumeral muscular dystrophy: Results of the REACH study.

Journal of neuromuscular diseases
2026

The Impact of Glycosylation on the Conformational Ensembles of β-, δ-, and γ Sarcoglycans.

bioRxiv : the preprint server for biology
2026

Screening for brain-related comorbidities in Duchenne muscular dystrophy: Construction, reliability, and validity of the BIND screener.

Developmental medicine and child neurology
2025

Implementation of Newborn Screening for Duchenne Muscular Dystrophy.

Hospital pediatrics
2026

Mechanisms of protein degradation in atrophying muscles: What have we learned during the past decade?

The Journal of biological chemistry
2026

Diagnostic Value of Muscle MRI in a Case of Very Late-Onset Becker Muscular Dystrophy.

Clinical neuroradiology
2026

Direct AMPK Activation Confers Mutation-Independent Therapeutic Benefit in Duchenne Muscular Dystrophy.

Journal of cachexia, sarcopenia and muscle
2026

Urinary glucose tetrasaccharide tracks disease activity in late-onset Pompe disease.

Neuromuscular disorders : NMD
2026

Refining functional phenotypes in an international cohort of untreated paediatric type 2 and 3 SMA patients using the Revised Hammersmith Scale.

Neuromuscular disorders : NMD
2026

Potential benefits of Ayurveda in Duchenne muscular Dystrophy: A case based analysis.

Journal of Ayurveda and integrative medicine
2026

Facial Weakness in Facioscapulohumeral Muscular Dystrophy: Objective and Patient-Reported Measures to Guide Reconstructive Interventions.

Facial plastic surgery &amp; aesthetic medicine
2026

Dual AAV gene therapy using laminin-linking proteins ameliorates muscle and nerve defects in LAMA2-related muscular dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy
2026

Exon-skipping rat model of muscular dystrophy.

Lab animal
2026

High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.

Nature medicine
2026

Frequent co-occurrence of AChR-positive myasthenia gravis in facioscapulohumeral muscular dystrophy suggests a novel disease association.

Journal of neurology, neurosurgery, and psychiatry
2026

[Chinese expert consensus on the diagnosis and treatment of Becker muscular dystrophy].

Zhonghua nei ke za zhi
2026

Neuromuscular and neuromechanical assessments of respiratory performance in the mdx mouse model of Duchenne muscular dystrophy across the natural history of disease.

Experimental physiology
2026

Feasibility of High-Density Surface Electromyography for the Detection of Neuromuscular Disorders in Children.

Muscle &amp; nerve
2026

Symptomatic Pneumoperitoneum After Percutaneous Radiological Gastrostomy in Patient With Duchenne Disease Dependent on Non-Invasive Mechanical Ventilation.

Open respiratory archives
2026

Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials.

Therapeutic advances in rare disease
2026

Improving angiogenesis ameliorates the efficacy of ASO-based exon skipping for the treatment of Duchenne muscular dystrophy.

Molecular therapy. Nucleic acids
2026

Identification and functional validation of intracellular protein partners of phosphorothioate splice-switching oligonucleotides using AP-MS.

Molecular therapy. Nucleic acids
2026

Muscle transcriptome profiling reveals novel molecular pathways and biomarkers in laminin-α2 deficient patients.

Acta neuropathologica communications
2026

Rare DMD Gene Duplication in a Lebanese Child With Duchene Muscular Dystrophy.

Clinical case reports
2026

From lipid switch to tissue repair: how resolvins reprogram macrophage polarization and function.

Immunometabolism (Cobham, Surrey)
2026

Molecular Mechanisms and Therapeutic Potential of DJ-1 in Skeletal Muscle Homeostasis and Disease.

Comprehensive Physiology
Ver todos os 17.095 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Distrofia muscular.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Distrofia muscular

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Wearable technologies in clinical trials for drug development: trends and emerging opportunities.
    Nature reviews. Drug discovery· 2026· PMID 41872333mais citado
  2. Prediction of relapse in myelin oligodendrocyte glycoprotein antibody-associated disease: external validation of the MOG-AR score.
    Journal of neurology· 2026· PMID 41870604mais citado
  3. Investigation of Walking Ability in 161 Patients With Duchenne Muscular Dystrophy.
    Clinical pediatrics· 2026· PMID 41866911mais citado
  4. CTLA4-Ig reduces proliferation and inflammatory gene expression in muscle fibroblasts, corresponding to less fibrosis and inflammation in mdx muscular dystrophy.
    American journal of physiology. Cell physiology· 2026· PMID 41855092mais citado
  5. Cracking the Code: Genotype-Phenotype Correlation Models in Sarcoglycanopathies.
    Annals of clinical and translational neurology· 2026· PMID 41853897mais citado
  6. Development of a DUX4-targeting antibody oligonucleotide conjugate as a therapy for FSHD.
    Nucleic Acids Res· 2026· PMID 41994867recente
  7. Predictors of quality of life in parents of children with rare diseases: a tertiary care center cross-sectional study in Saudi Arabia.
    Front Public Health· 2026· PMID 41994538recente
  8. Single nuclei/cell transcriptomics reveal DMD driven cell dynamics and mechanisms of fibroblast inflammatory tissue priming in human dystrophic muscle.
    Res Sq· 2026· PMID 41994144recente
  9. WNT5a-Mediated Aberrant Actin Filament Dynamics Drive Cardiac Pathogenic Phenotypes in LMNA-Related Emery-Dreifuss Muscular Dystrophy.
    Circulation· 2026· PMID 41993022recente
  10. Vertebral fractures and muscle function in glucocorticoid-treated individuals with Duchenne muscular dystrophy: a cohort study.
    Osteoporos Int· 2026· PMID 41991651recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98473(Orphanet)
  2. MONDO:0020121(MONDO)
  3. Distrofia Muscular de Duchenne(PCDT · Ministério da Saúde)
  4. GARD:7922(GARD (NIH))
  5. Variantes catalogadas(ClinVar)
  6. Busca completa no PubMed(PubMed)
  7. Artigo Wikipedia(Wikipedia)
  8. Q1137767(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Distrofia muscular
Compêndio · Raras BR

Distrofia muscular

ORPHA:98473 · MONDO:0020121
🇧🇷 Brasil SUS
Internações
2.340/ano
Prevalência BR
1:3500 (homens)
Custo SUS
R$ 6.780/internação
Dados
DATASUS 2024
Geral
CID-10
G71.0 · Distrofia muscular
CID-11
Ensaios
29 ativos
Medicamentos
2 registrados
MedGen
UMLS
C0026850
Repurposing
1 candidato
atalurenCFTR channel agonist|dystrophin stimulant
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades